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Abstract 
There is a large population of microorganisms which reside deep within the skin and 
are not easily accessible or removed without damaging the skin layers. Therefore, it 
would be useful to design an effective drug delivery system that could deliver the 
antimicrobial agent deeper into the outmost layer of the skin, the stratum corneum. 
The main objective of this study was to prepare a nanosized lipidic particulate drug 
delivery system that has an innate antimicrobial activity as well as the ability to carry 
an antimicrobial agent with the potential to deliver the drug through the skin. Similar 
to ethosomes and transfersomes, the use of edge activators such as sodium cholate 
hydrate, Span 80 and Tween 80, could make these lipidic nanoparticles more elastic 
and have the ability to be deformed allowing deeper penetration into the skin or 
applied topically. 
In this study, thin film hydration technique was used to prepare the conventional 
formulations of liposomes, ethosomes and transfersomes by first dissolving DPPC, 
SPC, cholesterol and edge activators (Sodium cholate hydrate, Span 80, Tween 80) in 
either chloroform or chloroform: methanol mixture. The samples were then hydrated 
by a PBS (pH 7.4), doubled distilled water or distilled water-ethanol mixture 
following rotary evaporation for 60 minutes. The conventional formulations either 
with or without the model drug (chlorhexidine) were compared with the purposely-
designed ultraflexible lipidic formulation, which is termed as propanosomes. 
Modifying the thin film hydration method, this study used propanol for the hydration 
step for the synthesis and optimisation of propanosomes. Propanol was selected over 
other solvents due to its more bactericidal property. All formulations were 
characterised using laser diffraction, zeta sizer and lipid extrusion techniques. The 
propanosomal formulations were visualised under TEM. The following size ranges 
were found with the following formulations: liposomes (1µm), ethosomes (6-8 µm), 
transferosomes (60-90 nm) and propanosomes (80-100 nm). These experiments also 
showed that ethosomes were more ultradeformable than liposomes and transfersomes 
as there was no change of the size upon extrusion. The propanosomal results showed 
that the mean particle size was inherited by transfersomes and deformability and 
charge were inherited by ethosomes concluding that the combining preparatory 
method of using transfersomes and ethosomes was successfully achieved. 
Antimicrobial studies on the formulations as disk diffusion testing was also conducted 
on the formulations. In conclusion, the results of this study have demonstrated that it 
is possible to synthesis and characterise novel lipidic particulate system and further 
optimisation on the nanolipidic system warrants potential application as drug delivery 
system for topical antimicrobial application. 
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1.1  Skin model 
Human skin is the main barrier for material permeation (Barry, 1983) and consists of 
inner skin region of 250 µm called the dermis and outer skin region of 50 µm known 
as the epidermis. The outer most layer of the epidermis is the stratum corneum (SC), 
often described as the horny layer of the skin and acts as a major biological barrier for 
absorption through the skin (Cevc, 2003).  
There are three possible ways through which the penetrants can follow to pass 
through the skin: – the hair follicles with associated sebaceous glands, the sweat 
glands and the continuous appendages across SC (see figure 1.1) (Barry, 2001). 
 
Figure 1.1: Simplified diagram of skin structure and micro routes of drug 
penetration: (1) via the sweat ducts; (2) across the continuous stratum corneum 
and (3) through the hair follicles with their associated sebaceous glands (Taken 
from Barry, 2001). 
 
Only 0.1% of fractional appendageal are available for transportation (Barry, 2001) 
and SC provides the major barrier for drug transportation due to its ‗brick and mortar‘ 
wall like structure (Barry & Williams, 1995). In this structure, the corneocytes of 
hydrated keratin consist of ‗bricks‘ embedded in a ‗motar‘ composed of multiple 
lipidic bilayers of ceramides, fatty acids, cholesterol and cholesterol esters. These 
bilayers form gel and liquid crystals domain regions. Most of the molecules pass 
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through this intercellular microroute and many techniques are emerging to disrupt this 
route (see in figure 1.2). 
 
Figure 1.2: Diagram showing the stratum corneum and two microroutes of drug 
penetration (Taken from Barry, 2001). 
 
1.2 Transdermal drug delivery 
The transdermal route for drug administration has many advantages over other 
pathways such as avoiding the haepatic first-pass effect, the potential for controlled 
drug delivery, fewer side-effects and improved patient compliance (Barry, 1983). The 
major barrier for effective transdermal delivery is the low penetration ability of drugs 
through the skin mainly because of the SC layer which consists of coenocytes 
embedded in a lipid matrix. The lipid matrix composed of highly organized bilayer, 
containing free fatty acids, ceramides, cholesterol and cholesterol sulphate (Elias et 
al., 1977). Lipid matrix acts not only like―glue‖ but also seals the spaces between the 
cell and the skin (Trotta et al., 2002). Hence, the SC makes it very challenging for 
drug to pass through the skin (Wertz & Downing, 1989). Transdermal drug delivery 
approaches may depend upon fluidising or destroying this lipid bilayer (Barry, 1995). 
 
  
4 
1.3  Liposomes 
Liposomes are small spherical nano-sized vesicles produced from phospholipids and 
other excipients such as cholesterol. Liposomes are vesicles made of concentric 
bilayers, which may entrap and deliver various molecules such as small drugs, genes 
and proteins (Barry, 2001; Samad et al., 2007). Liposomes were first discovered by 
Bangham et al. in 1964 when they were studying phospholipids as model biological 
membranes today and they have become important carriers in pharmaceutical 
sciences, biology, biochemistry and medicine. The word ―liposome‖ is derived from 
the Greek words: ‗lipos‘ meaning fat and ‗soma‘ meaning body. Structurally, 
liposomes are concentric lipidic bilayers, which are made up of phospholipid 
molecules consisting of hydrophilic head group and hydrophobic tail group. The head 
group is water loving (i.e. hydrophilic) and the tail group is water repelling (i.e. 
hydrophobic) (Kimball‘s, 1981). In a cell, the head layer of phospholipid focuses 
outside of the cell is attracted towards the water in the environment and another layer 
of the head focus inside of the cell. The bilayer structure is formed by the combination 
of one hydrocarbon tail of one layer, which faces the other hydrocarbon tail of the 
other layer (Dua, et al., 2012). In the past 15 years, several liposomal drugs have been 
approved. Liposomal formulations are being used commercially for antifungal, anti-
tumour and anti-bacterial agents (Samad et al., 2007). 
1.3.1 Composition of liposomes 
When phospholipids are exposed to water, they are self-assembled into double-
layered aggregate bilayers shielding the hydrophobic portion (alkyl chains) from 
water, resulting in formation of liposomes. Phospholipids can be divided into 
synthetic phospholipids such as dipalmitoylphosphatidylcholine (DPPC) (Figure 1.3) 
and natural phospholipids such as soya phosphatidylcholines (SPC). There is no 
specific structure of soya phosphatidylcholine. It is a mixture of many molecules. The 
nature phospholipids can be found as different chain lengths and degree of 
unsaturation and plant-extracted phospholipid such as SPC contains high degree of 
polyunsaturation in the hydrocarbon chains (New, 1990a). 
  
5 
 
Figure 1.3: Chemical structure of Dipalmitoylphosphatidylcholine (DPPC) 
1.3.2 Types of liposomes 
Based on structural parameters such as size and number of phospholipids bilayers, 
liposomes are classified as small unilamellar vesicles, oligolamellar vesicles, 
multilamellar vesicles, large unilamellar vesicles, and multivesicular vesicles. 
Liposomes are found within a size range of about 50-500 nm, but can also be as large 
as 5µm (Arshady, 1999) (see Figure 1.4 and  Table 1.1).  
 
Figure 1.4: Schematic representation of basic structures and different types of 
liposomes. (Taken from http://www.hindawi.com/journals/jdd/2011/863734/fig1/) 
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Table 1.1: Types of liposome (Taken from: Dohert, 2004) 
Types of vesicles Abbreviation Diameter Number of lipid 
bilayers 
Small unilamellar 
vesicles 
SUVs Around 100 nm Single bilayers 
Oligolamellar vesicles OLVs 0.1 – 1 µm Approximately 5 
lipidic bilayers 
 
Multilamellar vesicles 
MLVs 500 – 5,000 nm Concentric bilayers 
Large unilamellar 
vesicles 
 
LUVs 
 
200 – 800 nm 
 
Single bilayers 
Multivesicular vesicles MVVs >1 µm Multicompart-mental 
structure 
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1.3.3 General method of liposome preparation 
 There are many methods that can be used for preparation of liposomes. The most 
common and traditional method is the thin-film hydration method, also called hand 
shaking method or Bangham method (Szoka and Papahadjopoulos, 1980). 
1.3.3.1 Thin film hydration for preparation of liposomes 
Thin film hydration is the most common method for preparation of liposomes. For 
preparing liposomes, the lipids and cholesterol are first dissolved and mixed in an 
organic solvent to make a homogenous mixture. The solvent usually comprises either 
chloroform or chloroform: methanol (1:1 v/v). The major aim is to obtain a clear lipid 
solution for completely mixing the lipids. Once thoughly mixed, the organic solvent is 
removed using rotary evaporation to obtain a lipid film. Addition of aqueous phase 
with shaking generates a ―milky‖ suspension of liposomes. This procedure has been 
described in many publications with minor modification in each depending on the 
properties needed for the liposomes following hydration. For instance, Elhissi and co-
workers (2006) designed the vesicles to be ultradeformable by inclusion of surfactants 
in the lipid mixture prior to dissolution in the organic solvent. The prime limitation of 
the thin film hydration method is the low entrapment offered by the resultant vesicles 
and difficulty of generating liposomes on a large scale using this approach. However, 
at research level, this method is still widely used. 
1.3.4 Advantages of liposomes 
Liposomes may offer a range of advantages including enhancement of stability and 
manipulation of pharmacokinetics of the entrapped material. Drug degradation can be 
minimized by encapsulation of the drug in liposomes (Pinto-Alphandary et al., 2000). 
Previous research studies have demonstrated that liposomal formulations could 
enhance the targeting properties of the encapsulated drug and may also potentiate its 
therapeutic effect. Liposomes were first targeted for the treatment of intracellular 
pathogens (e.g. leishmaniasis and histoplasmosis) and life threatening systemic fungal 
infections (e.g. treatment of candidosis and aspergillosis by using amphotericin B-
encapsulated liposomes (Ambisome
®
). Liposomal formulations may also be effective 
for antibacterial infections (Alder-Moore et al., 2002; Fielding et al., 1999). 
Intracellular pathogens such as Salmonella, Mycobacterium, and Leishmania located 
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in the phagocytic cells of reticuloendothelial system (RES) or outside the RES (e.g. 
lung tissue infected with Klebsiella pneumonia) show sensitivity towards entrapped 
antibiotics delivered by liposomes (Constant et al., 2006). In addition, liposomes have 
been extensively studied as carriers of anticancer drugs such as doxorubicin (Doxil
®
) 
opening a new horizon towards the role of nanotechnology in anticancer drug 
development (Huang et al, 2008). 
1.3.5 Drawbacks of using liposomes 
There is extensive research investigating the potential use of liposomes as drug 
carriers, and a range of liposomal formulations are used in clinical trials (Maurer et 
al., 2001; Immordino et al., 2006; Chen et al., 2010). However, one major 
disadvantage of liposomal formulations, which also contribute as major obstacles for 
the licensing of many liposome-based products are the instability of liposomes during 
storage. This is aggregated by the presence of aqueous phase which increases the rate 
of phospholipid hydrolysis (Kensil et al., 1981; Grit et al., 1989) and oxidation (Hunt 
et al., 1981). Liposomes can also be destabilized due to vesicle aggregation, leading to 
leakage of the entrapped material (Elhissi et al., 2010). 
Another disadvantage of using liposomes is their fast elimination from the blood and 
the capture of liposomes by the cells of reticulo-endothelial system (Torchilin, 2005). 
Liposomes may be used for transdermal delivery of drug and could be employed in 
research as biological membrane models to predict how drugs and permeability 
enhancers interact with cells (El Magharby et al., 2008). 
1.3.6 Applications of liposomes 
Liposomes provide excellent advancement in dermal and/or transdermal 
bioavailability of drugs (Constant et al., 2006). As being a drug carrier, liposome may 
enhance drug permeability through biological membranes by facilitating the 
absorption of the drug through the percutaneous system (Constant et al., 2006).  
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Thus liposome-based formulations have been extensively studied for the following 
reasons: 
1. Enhancing the uptake of antigens for topical immunization (e.g. tetanus toxin) 
(Gupta et al., 2010). 
2.  Oxygen species scavengers for the prevention of cutaneous photodamage (i.e. 
sodium   ascorbyl phosphate) (Foco et al., 2005). 
3.   Enhancing the therapeutic effect of antihistaminic drug (i.e. cetirizine) via drug 
encapsulation (Elzainy et al., 2004). 
4.   For encapsulation of non-steroidal and steroidal anti-inflammatory substances 
(e.g. indometacin, hydrocortisone, dexamethasone) (Puglia et al., 2004; Cevc et al., 
2004; Sinico et al., 2005). 
5.   For antitumoral and antiviral drugs (e.g. tamoxifen, methotrexate, idoxuridine, 
acyclovir)  (Bhatia et al., 2004; Seth et al., 2004; Trotta et al., 2004; Seth et al., 
2003). 
6. For entrapment of immunosuppressive molecules (e.g. cyclosporin A), showing 
potential in the treatment of dermatological diseases characterized by an autoimmune 
T cell-mediated pathogenesis (Verma et al., 2004). 
Contrasting with expert‘s previous research also shows that liposomes are not able to 
penetrate through deeper inside the skin (Mezei et al., 1980). As per rule, they are 
believed to be deformed and transformed as fragments (Touitou et al., 1994). 
Therefore, for chemical composition size, shape, and lamallarity are all relevant for 
formulation (Fresta et al., 1996). Phosphatidylcholine have multi-functioning 
properties for different applications. Formulations prepared from unsaturated 
phosphatidylcholines are preferred to support skin regeneration, prevent skin aging, 
prevent development of acene and enhance penetration of other active agents like 
vitamins and their derivatives into the skin. For skin protection against sunburns, 
nanoparticles and DMS (Derma Membrane Structure) are used but hydrogenated 
phosphatidylcholine may also be used (Fresta et al., 1996) 
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1.3.7 Lipids and Liposome Composition 
An important parameter in liposomal properties is rigidity of the bilayers which is 
mainly influenced by lipid phase composition of the liposome, determining the 
liposomal properties including stability on storage and pharmacokinetic properties 
following in vivo administration (Chapman, 1975; Lee, 1975; Melchoir & Steim, 
1976; Phillips, 1972). When vesicles are kept below the phase transition temperature 
(Tc) of the lipid phase they are considered to be ‗solid‘ while when the preparation is 
stored above the phase transition temperature the vesicles are considered to be ‗fluid‘ 
and exhibit higher permeability of the encapsulated drug. Phase transition temperature 
of a given phospholipid is a function of the acyl chain length and it increases with 
increasing the length of the acyl chain. The phospholipids which can carry the bulky 
side groups, unsaturated chains or branched chains e.g. cyclopropane ring exhibit 
considerable decrease in the Tc. The head groups of acidic phospholipids also have a 
considerable influence on the phase transition temperature. For example, 
phosphatidyserine, phosphatidyglycerol, and phosphatidic acid.  
Another component to influence the bilayer fluidity and enhance liposome stability is 
cholesterol, which is a prominent component of eukaryotic biological membranes 
(Szoka & Papahadjopoulos, 1980). Cholesterol at high concentration may eliminate 
the phase transition temperature of the phospholipid, making drug release from the 
resultant liposomes less dependent on temperature (Tseng et al., 2007). 
1.4 Transfersomes 
In most of the published reports, it was observed that drugs applied on the skin tend to 
accumulate on the upper layer of the skin (Mezei and Gulasekharam, 1980; Mezei and 
Gulasekharam, 1982; Touitou et al., 1994; Fresta and Puglisi, 1996; Meidan et al., 
1998a; Cheng and Chien, 1999). As reported by Mezei (1992), liposomes are not 
expected to penetrate through the stratum corneum of the skin. However, the vesicular 
transportation of the drug is still debatable (Barry, 2001). To overcome the difficulty 
of poor skin permeability, various approaches have been proposed including the use 
of transfersomes and ethosomes. Cevc‘s group in 1991 introduced ‗transfersomes‘ 
which are the first generation of elastic vesicles (Figure 1.5).  
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Figure 1.5: a) Rigid liposomes consisting of double chain lipids in the presence or 
absence of cholesterol and  b) Transfersomes consisting of double chain lipids 
and an edge activator (Taken from Benson, 2006). 
Transfersomes is a registered trademark by the German Company IDEA, AG. The 
name means the ―carrying bodies‖, and is derived from the Latin word ‗transferre‘, 
meaning ‗to carry across‘, and the Greek word ‗soma‘, for a ‗body‘ (Prajapati et al., 
2011). They are classified into phospholipid and detergent-based types (Choi & 
Maibach, 2005) and are prepared by phospholipids and edge activators. An edge 
activator is a single chain of surfactants with a high radius of curvature, which 
destabilises the lipidic bilayer of the vesicle and increases the deformability of the 
bilayer (Duangjit et al., 2011). It was claimed by the inventors of this type of vesicle 
that transfersomes are highly ultra-deformable and can squeeze through the stratum 
corneum and have less than one-tenth of the liposomal diameter. Thus, for sizes up to 
200-300 nm they can penetrate through the intact skin (Fig 1.6) (Barry, 2001). When 
compared with subcutaneous administration, transfersomes improved in-vitro skin 
permeation of various drugs, penetrate the intact skin from in-vivo studies and 
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effectively transfer the therapeutic amount of drugs (Chang et al., 2007; Elsayed et al., 
2006; Viriyaraj et al., 2009).  
 
Figure 1.6: Ultra deformable transfersome squeezing through minute pores in 
the stratum corneum, driven by the water concentration gradient. The liposome 
with edge-activators thus penetrates from the horny layer surface (relatively dry) 
to the wet viable tissues (modified from Cevc et al., 1996) (Taken from Barry, 
2001). 
 
There are two important features to be considered. Firstly, in non-occlusive 
conditions, transfersomes require a hydration gradient to penetrate, driving the 
transfersomes through the horny layer in order to reach a depth of at least 30 µm 
(Aguiella et al., 1994). Secondly, transfersomes work best in in-vivo conditions, by 
virtue of their high and self-optimizing deformability (Choi & Maibach, 2005). 
1.4.1 Functions of Transfersomes 
Transfersomes can be described as lipid vesicles having deformability that 
facilitates their penetration through the pores of the skin even though the 
vesicle size is much larger than the pore size (Prajapati et al., 2011). 
 
1. When transfersomes are applied to the skin, due to their deformability they 
exploit the hydrophilic pathways or ‗pores‘ in-between the cells by widely 
opening the gaps in the SC layer and thus passing through together with its 
drug cargo without losing their integrity (Figure 1.7) (Prajapati et al., 2011). 
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2. Transferosomes are capable of transporting low or high molecular weight 
drugs, however, that is influenced by a range of formulation factors such as 
transferosomal composition, drug entrapment efficiency and the detailed 
application conditions such as pretreatment of vesicles, duration of skin 
exposure to the vesicles and the volume of formulation (Choi & Maibach, 
2005). 
 
3. In non-occlusive application, the flexibility of the transfersomes reduces the 
vesicular rupture in the skin and thus allows them to follow natural water 
gradient across the epidermis (Prajapati et al., 2011). 
 
4. Transferosomes may protect the drug from degradation and provide an 
effective reservoir for sustained drug release (Cevc 1996). 
 
 
5. Transferosomes can penetrate the SC layer either by intracellular or 
transcellular routes. Figure 1.7 shows the drug penetration across the human 
skin via these two routes (Schatzlein & Cevc, 1995; Panchagnula 1997). 
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Figure 1.7: Schematic diagram showing the two microroutes of penetration in 
biological membranes (Taken from Prajapati et al., 2011). 
1.4.2 Advantages of transfersomes 
Transfersomes have advantages in the field of cosmetics and dermatology. It has been 
observed that transfersomes significantly improve the drug delivery via the 
transdermal route compared to conventional liposomes.
Transferosomes have been reported to be safe for application on skin and they may 
improve hydration of aged skin (Cevc et al., 2001).  
1.4.3 Transfersomes versus other Carrier systems 
Transfersomes can prolong the release and improve the pharmacological activity 
of drugs in-vivo (Jain et al., 2004). In this study, in-vivo performace of selected 
formulation was evaluated by using a carrageenan-induced rat paw edema model. 
It has been reported that transfersomes encapsulating dexamethasone can provide 
82.3% inhibition of paw edema, compared to conventional liposomes ointments, 
which reduced the edema by around 38.3% and 25%, respectively. Similarly, 
triamcinolone acetonide, at a dose of 0.2 mg /cm
2
 was able to suppress 75% of the 
edema in the ear of the rat over a period of 48 hours. In contrast, conventional 
formulation of this drug required almost a 10-fold increase in concentration to 
induce the same pharmacologic activity (Cevc & Blume, 2003). Other studies 
using transferosomes have reported similar results for Diclofenac where the 
therapeutic effect was prolonged and the concentration of the drug increased 
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almost by 10 times in tissues under the skin compared to commercial hydrogel 
formulations (Cevc & Blume, 2001). 
In their studies, Paul et al (1998) showed that large molecules could be transferred 
through intact skin using transferosomes, resulting in successful immunization 
with a protein antigen. In that study, gap junction protein (GJP) were encapsulated 
in transfersomes and applied to the skin. The results showed that the specific 
antibody titers were higher than those elicited by subcutaneous injection of the 
protein using transfersomes, mixed micelles or conventional liposomes (Paul et al., 
1998). Similarly, Cevc (2003) showed that the transdermal delivery of insulin by 
transfersomes through the skin was equivalent to insulin injected subcutaneously. 
In addition, Kim et al. (2004) investigated the effect of cationic transfersomes 
(containing DOTAP and Cholate) on transdermal delivery of DNA in mice. The 
results revealed that GFP  (Green Fluorescent Protein) expression to be very high 
compared to that of free gene in PBS solution, and expression was detected in 
distant organs like liver and lungs. Thus, transfersomes may be developed further 
as non-invasive protein and gene delivery system (Cevc & Blume, 2003).  
1.4.4 Mechanism of transfersome penetration through biological 
membranes 
One mechanism of transferosomal penetration through the skin is by utilising its 
elastic nature, resulting in enhanced delivery of the encapsulated drug across the 
SC layer and subsequent drug release at the site of action (Honeywell-Nguyen & 
Bouwstra, 2003). Fang et al. (2001) investigated the mechanism of vesicular sytem 
across the skin with soybean PC liposomes containing enoxacin. Their results 
showed that after 12 hour of drug treatment, drug permeation across PC-treated 
skin was higher than that of nontreated skin. Similarly, Verma et al. (2004), using 
a model hydrophilic drug, demonstrated that PC liposomes carry both entrapped 
and unentrapped drug through the SC layer to the deeper layers of the skin. 
Transfersomes provided a penetration efficiency of 5-fluorouracil trasnfersomes 
through the SC of 13.5% when the drug entrapment efficiency was as low as 8.8% 
(El Maghraby et al., 2001). 
However, it is agreed that higher drug entrapment in transferosomes is necessary 
to maximize the drug transportation through the SC (Honeywell-Nguyen et al., 
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2003; Honeywell-Nguyen et al., 2003). The other proposed mechanism of 
enhanced penetration of transferosomes is attributed to the detergent-based elastic 
nature of the vesicles. Honeywell-Nguyen et al. (2003) proposed that detergent-
based elastic vesicles can facililate drug transport by fast partitioning in the SC 
and do not penetrate into the deeper layers. There are four major steps in 
determining the effectiveness of the elastic vesicles. The first is about drug 
association with the vesicle bilayers, while the second is about the partitioning of 
vesicles into the SC. The third is the drug release from the vesicles once it is in the 
SC and finally, the fourth case is the portioning of the free drugs in the SC and 
subsequent delivery to the systemic circulation (Honeywell-Nguyen et al., 2003).  
1.4.5 Preparation methods of transfersomes 
The general method for preparation of transfersomes is the thin-film hydration 
technique described earlier. A thin film is prepared, hydrated and then the resultant 
vesicles are reduced to the desired size by sonication and homogenized via 
extrusion through polycarbonate membrane filters. 
1.4.6 Application of Transfersomes 
The following are the application of transfersomes for transdermal drug delivery. 
1) Diffusion of large molecules across the skin 
Due to higher molecular weight of some drugs (e.g. proteins), they are unable to 
cross through the skin and reside at the upper layer (SC) of the skin itself. In order 
to overcome this problem, transferosomes are non-invasive vehicles of large 
molecules for successful penetration across the skin. For example, transfersomes 
(transfersulin) encapsulating insulin can help to overcome the inconvenient 
subcutaneous administration of the drug (Planas et al., 1992). 
Transfersomes are used as carriers for controlled release of interferon-α (INF-α) 
and interleukin-2 drug and for increasing the stability of drugs having 
immunomodulatory effects (Choi & Maibach, 2005). Transfersomes are widely 
used for carrying the proteins and peptides, as both of them are biogenic molecules 
due to which their transportation is difficult. When given via oral administration, 
the proteins and peptides are degraded in the gastointestinal GI tract whilst 
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transdermal penetration is not possible because of their large size. The 
bioavailablity obtained using transfersomes seems to be similar to that of 
subcutaneous injection of the same protein  (Trotta et al, 2004; El Maghraby et al., 
2000). 
2)  The topical delivery of vaccines for transdermal immunization 
Due to their ultradeformable capability, transfersomes can be used to deliver 
vaccines transdermally following topical administration of vaccine in 
transferosome formulation. Trasnfersomes may entrap proteins such as integral 
membrane protein, human serum albumin and gap junction protein, hence, can be 
used for delivery of vaccines, offering avoidance of the painful injections. 
Moreover, higher IgA levels can be obtained with transferosomal formulations of 
vaccine, for instance, by transcutaneous delivery of hepatitis-B vaccine using 
transferosomes (Song & Kim, 2006).  
When compared with subcutaneous injections, transfersome-based formulations of 
local anaesthetics showed similar permeation as subcutaneous injections 
demonstrated with studies employing lignocaine and tetracaine (Prajapati et al., 
2011). In addition, the pain sensitivity is similar to subcutaneous bolus injections 
(80%) and the effect may last longer (Prajapati et al., 2011). 
3)  Transdermal deliveries for anti-cancer and herbal drug  
Tansdermal delivery of the anti-cancer drug methotrexate via transfersomes 
showed ability to treat skin cancer. The presence of transfersomes within the skin 
structure may help for the provision of the nutrients and maintain the functions of 
the skin. Encapsulation of capsaicin provided better topical application compared 
to free capsaicin (Benson, 2006; Xiao-Ying et al., 2006). 
1.4.7  Limitation of transferosomes 
Transfersomes are chemically unstable because of their liability to oxidative 
degradation. Purity of natural phospholipids is another limitation against adoption 
of transfersomes as drug delivery vehicles. Also, transfersomal formulations are 
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expensive, owing to the high cost of some pure lipid ingredients used in 
formulation of these systems (Prajapati et al., 2011). 
1.5 Ethosomes  
Another specially designed vesicle able to allow transdermal delivery is 
ethosomes, which are non-invasive delivery carriers that allow the drug to reach 
the deeper skin layers and possibly the systemic circulation. They are a soft, 
malleable vesicles, which are actively, enhances the delivery of entrapped drugs. 
Ethosomes are composed mainly of phospholipids (e.g. phosphatidylcholine, 
phosphatidylserine, phosphatitic acid), high concentration of ethanol (20-45%) and 
water (Anitha et al., 2011). Touitou (2002) observed that ethosomes might 
enhance delivery of drug to the deep strata of the skin or to the systemic 
circulation (Anitha et al., 2011). Due to ethosomal high malleability, it may 
permeate through human skin and into the systemic blood circulation (Jain et al., 
2004; Lopez-Pinto et al., 2005; Paolino et al., 2005; Touitou et al., 2000). 
According to Perez-Cullell et al. (2000) fluid liposomes can delivered more 
fluorescence into stratum corneum than did rigid liposomes (Barry, 2001). 
Ethosomes are deformable liposomes containing higher amount of ethanol (up to 
45%). It was proposed that alcohol fluidizes the ethosomal lipids and stratum 
corneum lipids, thus allowing the soft malleable ethosomes to penetrate 
(Ainbinder et al., 2005; Barry, 2002). The size range of ethosomes varies from 
tens of nanometers to micrometers (Anitha et al., 2011). The ethanol content may 
similar to surfactants as in case of transferosomes, conferring 10 times higher 
deformability of the vesicles (Godin et al., 2003; Jain et al., 2004).  
1.5.1 Mechanism of permeation enhancement using ethosomes  
As described previously by Touitou (2002), the exact mode of permeation 
enhancement using ethosomes is unclear. However, it is believed that the higher 
concentration of ethanol in ethosomes disrupts the lipid bilayer in the SC making it 
more permeable and thus giving the ethosomes a higher ability to squeeze through 
the small opening in the SC lipid (Touitou, 2001). 
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Substances that reversibly reduce the barrier resistance of the SC, such as ethanol, 
are commonly described as permeation enhancers (Anitha et al., 2011). Ethanol 
can interact with the polar head group of the lipid molecules, resulting in reduction 
of the melting point of the stratum corneum lipid, thereby increasing lipid fluidity 
and cell membrane permeability (Touitou et al., 1999). However, due to the 
interdigitation ethanol causes to the lipid bilayers, it was commonly believed that 
vesicles couldnot coexist with high concentrations of ethanol. Currently, ethanol 
might be used in relatively low concentrations in liposome formulations (Touitou, 
et al., 2000). Ethanol is a volatile solvent which can be easily evaporated at skin 
temperature (Anitha et al., 2011), leaving the supersaturated concentration of the 
drug in formulation. This may influence the drug flux across the membrane. Also, 
ethanol may alter the solubility of the SC, facilitating drug delivery (Verma, 
2004). 
In current studies, ethanol is found in low concentration in liposomal formulations; 
7-10% for transfersomes. However, higher ethanol concentrations are used in 
proniosome formulations (30-50%) (Fang et al., 2001; Vora et al., 1998). Figure 
1.8 shows how ethosomes may enhance penetration of drugs through lipid 
bilayers. 
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Figure 1.8: Diagrams showing the mode of drug penetration through lipid 
bilayers using ethosomes (Taken from Anitha et al., 2011). 
1.5.2 Composition and preparation of ethosomes 
Ethosomes are vesicular carriers composed of hydro-alcoholic or 
hydro/alcoholic/glycolic phospholipid in which the concentration of alcohol(s) is 
relatively very high (Friend, 1988).  
Ethosomes can be prepared using the conventional thin film hydration technique 
(mentioned in chapter 2) or by addition of aqueous phase in a controlled manner to 
the alcoholic solution of phosphatidylcholine. 
A. Cold method - In this method, phospholipids, drugs and other lipid 
materials are dissolved in ethanol in a covered vessel at room temperature 
by vigorous stirring with the use of mixer. Either Propylene glycol or other 
polyol are added while stirring (Jain, 2004). The mixture is heated to 30 
º
C 
in a water bath. In a separate vessel the water is heated to 30 
º
C  and added 
to the mixture followed by stirring for 5 mins (Touitou, 2000a). The size of 
the ethosomal formuation can be decreased using either by sonication or 
extrusion and the formulation is then finally stored in the refrigerator 
(Manosroi, 2009). 
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B. Hot method – In this method, phospholipids are dispersed in water by 
heating in a water bath (40 
º
C) until a colloidal suspension is obtained 
(Jain, 2004). In a separate vessel, ethanol and propylene glycol are mixed 
and heated to 40 
º
C and once it reaches the desire temperature the organic 
phase is added to the aqueous one (Bhalaria, 2009). Depending on the drug 
hydrophilic/hydrophobic properties, it is either dissolved in water or 
ethanol solvent. The size of the ethosomal formulation can be decreased 
using probe sonication or extrusion (Touitou, 1996). 
1.5.3 Advantages of ethosomes 
In comparison to complicated methods such as iontophoresis and phonophoresis, 
ethosomes may be more capable of delivering large molecules such as peptides 
and protein molecules. It offers low risk and high patient compliance when it is 
administrated as semi-solid formulation (gel or cream). Ethosomes also have 
applications in pharmaceutical, veterinary, and cosmetic fields (Gangwar, 2010). 
1.5.4 Ethosomes vs other carrier system 
Ethosomes are similar in their structure to liposomes only difference in 
composition. Liposomes composed of phosphatidylcholine and cholesterol 
whereas ethosomes are made of high concentration of ethanol (Chourasia et al., 
2011). The value of ethosomes lies in their capability of increasing the transdermal 
permeation of the entrapped material compared to liposomes or drug solutions of 
mixture containing ethanol and water (Dubey et al., 2007; Godin et al., 2003; 
Touitou et al., 2001). 
The efficacy of ethosomes by increasing the entrapped drug for transdermal 
delivery is similar to that of transfersomes. In a study conducted by Elsayed et al. 
(2006), they reported that ethosomes have increased the transdermal permeability 
of the entrapped drug ketotifen when compared with trasnfersomes (Chourasia et 
al., 2011). 
Godin et al. (2004) indicated differences in the data and they explained that 
existence of osmotic gradient across the skin was not important contrasting from 
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the data that was observed with elastic vesicles where permeation enhancement 
occurred only in non-occlusive conditions (Choi & Maibach, 2005). 
Addition of ethanol in ethosomes can provide high flexibility of the vesicles to 
squeeze through the skin pores that are much smaller in diameter than the vesicles. 
Thus, ethosomes are much more efficient in delivery of the drug in terms of 
quantity and depth when compared to conventional liposomes that tend to 
accumulate at the upper layer of the skin due to the stratum corneum barrier 
(Touitou et al., 2001). In other research articles, it has been observed that due to 
the presence of ethanol, ethosomes provide good storage stability of the vesicles 
(Dubey et al., 2007).                  
1.5.5 Therapeutics application of ethosomes 
Ethosomes are mainly used for transdermal route of drug delivery of various 
molecules. When tested, ethosomal preparations are used as replacement for 
liposomal preparation as they are much more effective permeation enhancers. 
Ethosomal carriers are used for delivery of hydrophilic and impermeable drugs. 
(Akiladevi & Basak, 2010). 
1.6 Vesicle characterisation  
The characterisation of the vesicular formulation was performed using the 
following techniques:- 
1.6.1 Lipid extrusion of vesicles 
Lipid extrusion is a technique in which multi-lamellar liposomes are forced 
through filters with defined pore sizes in order to optimise the size and size 
distribution of the vesicles. This technique is very popular for producing 
unilaminar vesicles (Hope et al., 1993). Extrusion of MLVs through polycarbonate 
membrane filters may lead to formation of a homogeneous population of LUVs 
(40-150 nm size range) (Hope et al., 1993).  
1.6.2 Transmission Electron Microscope (TEM) 
Transmission electron microscope (TEM) applies the same principle as light 
microscope, but uses electron in place of light. The wavelength of the light in light 
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microscope is the reason for poor resolution, whereas TEM uses ―electrons‖ as a 
―light source‖ which has much less wavelength compared to light microscope and 
provides 1,000 times better resolution. Due to its high magnification effect, TEM 
can be used in various research fields such as in medical, biological and material 
science (Stadtlӓnder, 2007). TEM can magnify the specimen within a range of 
500-500,000X (Flegler et al., 1993). 
In TEM the electron are projected through an ultrathin slice of the specimen and 
produces two-dimensional images.  
1.6.3 Sonication for size reduction of lipid particles 
Sonication is a commonly used technique for typically producing SUVs having 
size range of 15-50 nm. The most commonly used instruments are probe sonicator 
and bath sonicator for successfully producing SUVs (Dau, 2012). Sonication could 
be easier and less time consuming than extrusion for generation of small vesicles.  
Bath sonicators are used for homogenisation of the suspension which is done 
through the walls of the plastic/ glass tube where sample is present. Probe 
sonicators employ a tip (probe) that applies high ultrasound energy on the 
liposomal suspension, causing disruption of the lipidic bilayers (Dau 2012). The 
excessive heat generated during probe sonication may cause lipid degradation and 
contamination with the metal leaching from the probe (Hope et al., 1993). Due to 
these disadvantages bath sonicators might be preferred for SUV preparation, 
however, bath sonication is time-consuming (Dau, 2012). 
1.6.4 Particle size analyser 
The measurement procedure based on the fact that on modern laser diffraction 
device (LD) spatial distribution of scattered light is a function of the particle size 
of the analysed sample. The phenomena of light diffraction on particles can be 
vividly presented. As the stone hits the water surface, it forms various concentric 
rings of waves. The waves near the site of impact create highly intensive waves 
while the intensity decreases as moving away. Higher waves are created by larger 
stones and smaller waves are created by smaller stones. Similar phenomena take 
place for particles when illuminated. The LD measures the intensity of different 
rings and distance between the illuminating particles. The phenomena occurring 
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on illuminating particles are called light scattering wherein the scattering of the 
light is emitted in all directions. The spatial distribution of scattered light is 
commonly called the scattering pattern of particles. The scattering of the particles 
depend on the ratio of particle diameter (D) and the wave length of the incident 
light (λ). Based on D/ λ ratio the scattering pattern distinguished among the 
Fraunhofer, Mie and Rayleigh scattering (Stojanović & Marković, 2012). 
When the particle size is 5-6 times larger than λ then it forms Fraunhofer 
scattering pattern. When the particle size is less than λ (e.g 10 times) then it forms 
Rayleigh scattering pattern and when the D/ λ ratio is around one it forms Mie‘s 
scattering (Stojanović & Marković, 2012). 
In practice, the wavelength of the light source devices range from 633 to 900 nm 
(Keck et al., 2008) so that only particles larger than 4.5 µm can be analysed by 
Fraunhofer‘s approximation, and smaller by Mie‘s theory. Smaller particles 
scatters light of a lower intensity to larger angles, while the larger particles 
scattered light of relatively stronger intensity toward smaller angles. Since the 
intensity of scattered light to the front decreases with decreasing particle size, 
thereby sensitivity of the device is reduced and there is a limit of detection of 
particles below a certain size. However Mastersizer 2000 is limited for particle 
size detection from 0.02 - 2000 µm. The intensity of scattered light can be 
measured as laser beam passes through a dispersed particulate sample. The data is 
then analysed to calculate the size of the particles that created the scattering 
pattern (Mastersizer 2000 user manual, 2007). The machine analyse the particle 
size based on Fraunhofer and Mie‘s theories (Stojanović & Marković, 2012). 
 
The dispersed sample particle passes through the focused beam of light and 
scattered the light at characteristic spatial angles. The Mastersizer 2000 uses two 
sources of light, one light source: HeNe laser which is a source of red light of 
wavelength of 633 nm placed in the axis of the instrument and the other light 
source is emitted by LED which is blue light of wavelength of 455 nm. In addition 
to the conventional detector for small angels in the form of concentric rings 
located in front of the measuring zone in the axis of the device, there are additional 
side detectors for the light scattered at angles smaller and greater than 90º 
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respectively. The Fourier lens is placed behind the measuring zone. There is also a 
filter separating the vertical and horizontal polarized light. After completion of the 
measurements the raw data of the software analysed using defined optical 
parameters. The standard data shows in LD measurements are marked as d (0.1), d 
(0.9) and d (0.5). D (v, 50) is the mass median diameter (marked by lowercase v) 
of the volume distribution. It is expressed in microns and indicated that 50% of the 
sample has a size smaller than that value, whereas 50% have a larger size. D (v, 
0.1) indicates that 10% of the sample has a size smaller than that value, whereas D 
(v, 0.9) indicates that 10% are larger in size (Stojanović & Marković, 2012). 
 
1.6.5 Zeta potential analyser 
Zeta potential analyse the surface charge of the particle in a colloidal solutions. 
Nano particles have a surface charge which attracts the thin layer of ions of 
opposite charges to its surface. This double layer of particle travel with nano 
particle as it diffuses throughout the solutions (Zeta potential manual). 
The particle surrounded by liquid exists as two parts: inner region which is called 
Stern layer and outer layer consisting of diffuse region were they bound less 
firmly. Within the diffuse layer consist of notional boundary wherein ions and 
particles form stable entity. When the particle moves the ions also moves within 
these boundaries and the ions beyond this boundary stay within the bulk dispersant 
medium. The potential at this boundary is called zeta potential. The magnitude of 
zeta potential gives stability to the colloidal system. If the particles in the 
suspensions possess large positive or negative charge, then all the particles will be 
moving away from each other as they tend to repel each other as their will be no 
tenderacy for the particles to come together. However particle possessing lower 
zeta potential then no force can prevent them to come close to each other. The 
general dividing line for knowing the particle stability and instability are either  
+30 mV or -30mV i.e. particles which are more positive than +30 mV and more 
negative than -30mV are considered to be more stable. However, particles 
possessing different densities compare to dispersant medium are more prone to get 
sediment (Malvern Tec Note). 
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1.7 Chlorhexidine 
As shown in Figure 1.9, chlorhexidine is an antimicrobial agent having a chemical 
formula of 1,1′- hexamethylene-bis-5-(4-chlorophenyl) biguanidide or 1:6 di (4-
chlorophenyl-diguanido) hexane is a symmetric molecule with two ionizable 
guanidide moieties (Zeng et al., 2009).  
 
Figure 1.9: Chemical structure of Chlorhexidine [1:6 di (4-chlorophenyl-
diguanido) hexane] (Taken from Lim and Kam, 2008) 
Chlorhexidine (CHX) has a pKa value of 2.2 and 10.3 which makes it dicationic 
on a wide range of physiological pH values (Nerurkar et al., 1995). Its molecular 
weight is 505.45 g. It is an antimicrobial agent which is effective against both 
gram positive and gram negative bacteria, but with higher activity against gram 
negative bacteria owing to its negatively charged peptidoglycan layer cell wall to 
which the cationic granidium groups of CHX drug are believed to bind, acting as 
both bacteriostatic and bactericidal (Zeng et al., 2009). 
Clinically, an amount of 2% of CHX in aqueous solution is used as antibacterial 
agent for the treatment of root canals (Zebnder, 2006). CHX is mostly used in its 
salt form such as CHX diacetate, dihydrochloride or digluconate as the preferred 
use of the salt form of the drug is attributed to its free base form being very 
insoluble in water. Saturated solutions of CHX diacetate (CHX-Ac2) and 
dihydrochloride (CHXCl2) have 2% and 0.2 % of CHX concentration respectively 
(Nerurkar, et al., 1995). The digluconate salt is clinically rised as diluted solution 
(2%) and available at much higher concentration of 20% (w/v) (Gjermo, 1989). 
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CHX is used as antimicrobial agent in endodontic therapy (Dolby, et al., 1972; 
Gjermo, 1989; Senior, 1976; Wang and Peng, 2006). CHX drug was developed as 
antiseptic agent by imperial Chemical industries, (Manchester, UK) in 1950s 
(Davies et al., 1954). In medical practices, it is widely use as antiseptic agent and 
an ingredient in personal hygiene formulations such as in mouthwashes and 
toothpastes (Denton, 2000). 
1.7.1 Chemistry and physical characteristics of CHX 
CHX solutions are colourless, odorless, and have an extremely bitter taste 
(Denton, 2000). The N- chlorinated derivatives of CHX when used topically, it 
covalently binds with the proteins of skin mucosa resulting in persisting anti-
microbial effect with limited systemic absorption, even after oral ingestion (Boyce 
et al., 2002; Rushton, 1977; Cowen et al., 1979). 
1.7.2 CHX mechanism of action 
CHX disrupts the bacterial cell wall by adsorbing itself to the phosphate 
containing protein components. At lower concentration, it has bacteriostatic effect 
as it penetrates inside the bacterial cytoplasmic membranes causing leakage of 
cytoplasmic components. At higher concentration of CHX, it has bactericidal 
effect by forming irreversible precipitates with the intracellular adenosine 
triphosphate and nucleic acids after entering the cytoplasm via the damaged 
cytoplasmic membrane (Denton, 2000) (Figure 1.10). 
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Figure 1.10: A flow diagram showing the action of CHX on bacterial cell wall 
at Bacteristatic condition. 
 
CHX has bacteriostatic, bactericidal, fungicidal, fungisatic and antiviral properties 
(Davies et al., 1954; Denton, 2000). Longer exposure of CHX can increase the 
bactericidal effect against a wide range of bacteria (Figure 1.11). However, CHX 
has minimum effect against acid-fast bacilli or heat-resistant bacterial spores.  
Chlorhexidine 
Phosphate protein 
components 
Bacterial cell wall 
Penetrate 
Leakage of cytoplasmic 
component 
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Figure 1.11: A flow diagram showing the action of CHX on bacterial cell wall 
at bactericidal condition. 
 
1.7.3 Application of CHX drug 
1) Oral antiseptic 
CHX is widely used in mouthwash solutions, dental gels and toothpastes. It exerts 
bacteriostatic action when used in mouthwash solutions, were in it binds 
electrostatically to the oral mucosal surfaces, hence inhibiting dental plaque 
formation (Gjermo, 1989; Bral et al., 1988). 
2) Hand disinfectant 
 The temporary habitation of hand flora (S. aureus and gram negative bacilli) on 
the superficial skin layers are associated with nosocomial infection and existence 
of resident flora (coagulase negative S. epidermidis) within the deeper skin layers 
are less likely to be pathogenic (Boyce et al., 2002). 
CHX solutions are used as surgical hand disinfectants (Mulberry et al., 2001; 
Pereira et al., 1997; Larson et al., 2001).  
Chlorhexidine 
Precipates  formation with ADP & nucleic acid 
Destroys cytoplasm membrane 
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The efficiency of skin antiseptic are measured in terms of log reduction of 
bacterial counts, where 1-log represents 10 fold decrease in bacterial counts (i.e. 
90% bacterial elimination) and 20-fold decrease meaning 99% bacterial 
elimination. Although presence of total bacterial count does not consider the 
pathogenicity of bacterial remaining. However, the pathogenic bacteria (S. aureus) 
present onto the superficial skin of the hand are removed by hand washing. As 
suggested by US FDA, 1-log reduction of bacterial count at 1 min, 2-log reduction 
at 5 mins and 3-log reduction at 10 mins (Boyce et al., 2002). 
The most effective antiseptic agents are alcohols followed by CHX and then 
povidone iodine. However, residual antimicrobial activity is fastest for CHX drug. 
Formulations containing both CHX and alcohol are most antimicrobial effective 
(Gjermo, 1989). 
Newer handwash regimens contain CHX and alcohol hand rubs and they provide 
greater reduction in bacterial count compared to traditional methods of using 
surgical hand antiseptisis involving brush and sponge with either CHX gluconate 
(4%) or povidone iodine (10%) (Hibbard et al., 2002).  
In a non-blinded trial observation, it was found that instead of using CHX (2%) 
and isopropyl alcohol (70%), the combined use of CHX and isopropyl alcohol 
achieved highest antibacterial count reduction and statically showed marked 
antimicrobial activity (Hibbard et al., 2002). Overall, the data show that CHX is a 
better antiseptic handwash and surgical skin preparation compared to iodine (Lim 
& Kam, 2008). 
3) Venepuncture and vascular access 
CHX mixture with alcohol provided superior antseptic for skin preparations prior 
to venepuncture and vascular access (Lim & Kam, 2008). Other benefits include 
shorter onset of action and long lasting antimicrobial activity in presence of 
pretentious material such as blood (Mimoz et al., 1999). A meta-analysis of 8 
randomized trials, alcoholic CHX showed 50% risk reduction in catheter related 
bloodstream compared with povidone iodine. The risk reduction is due to the 
prolonged anti-microbial activity of CHX and its efficiency in the presence of 
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blood (Chaiyakunapruk et al., 2002). A 2% alcoholic CHX is used for skin 
antisepsis as per the guidelines for the preparation of intravascular catheter-related 
infectious disease (Baer, 2006). 
4) Central venous catheters (CVCs)  
CHX-silver sulfadiazine-treated CVCs may reduce the bacterial colonization. 
CHX disrupts the bacterial cell membrane which influx the silver ions into the 
bacterial cell where they bind to the DNA helix and impair bacterial replication 
(Mermel, 2001; Pearson et al., 1997; Logghe et al., 1997). The antimicrobial 
substances are dissolved in the surrounding tissues by leaching out the catheter 
and prohibiting the bacterial colonization and bacterial growth (Pearson & 
Abrutyn, 1997; Logghe et al., 1997; Tennenberg et al., 1997; Maki et al., 1997; 
Heard et al., 1998). 
5) Placement of epidural catheters 
In order to reduce the risk of epidural infections for skin, antiseptic solutions are 
used prior to the insertion of epidural catheters. It is suggested that bacterial 
colonization leading to epidural infection can be reduced along the epidural 
catheter. In a random controlled trial, the efficacy of chlorhexidine was tested 
against the controlled trial in which significant reduction of bacterial colonisation 
was observed along the catheter tips compared to control drug (Lim and Kam, 
2008). 
1.7.4 Adverse Effects of Chlorhexidine 
In dental care products of chlorhexidine, adverse effects such as staining teeth, 
salivary calculus formation and transient dulling of taste sensation are rarely 
reported (Rushton, 1977; Gjermo, 1989).  
1.8 Alcohol antiseptics 
It has been observed that ethyl alcohol (ethanol) and isopropyl alcohol (propanol) 
(60-90% solution) have recently gained acceptance as hand antiseptics. Even 
though both of them have the germicidal characterstics, with better bactericidal 
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properties than bacteriostatic properties against vegetative forms of bacteria (Gram 
+ and Gram -). These alcohols can also act as tuberculocidal, fungicidal, and 
virucidal against enveloped viruses but not effective against bacterial spores and 
nonenveloped viruses. The optimum bactericidal activity is in the range of 60-90% 
solution in water (v/v) and their bactericidal activity drops sharply when diluted to 
a concentration below 50% (Morton, 1950; Ali et al., 2001). 
Previous studies have shown that at concentration of 60-80%, ethyl alcohol is a 
potent virucidal agent for lipophilic viruses (e.g. herpes, vaccinia, and influenza 
virus) and many hydrophilic viruses (e.g. adenovirus, enterovirus, rhinovirus, and 
rotaviruses but not hepatitis A virus (HAV) or poliovirus) (Tyler, et al. 1987, 
Kurtz et al., 1980). On the other hand, isopropyl alcohol is not active against non-
lipid enteroviruses but fully active against lipid viruses. Moreover, isopropyl 
alcohol is slightly more bactericidal than ethyl alcohol for E. coli and S. aureus 
bacteria (Coultthard & Sykes, 1936). Isopropyl alcohol (20%) is effective in 
killing the cysts of Acanthamoeba culbertsoni (560) as chlorhexidine, hydrogen 
peroxide, and thimerosal (Turner et al., 1999).  
1.9 Experimental plan 
The experiments were performed by preparing control formulation (Liposomes, 
Ethosomes and Transfersomes) and ultraflexible nanosized lipidic formulation by 
thin film hydration either with or without the drug chlorhexidine. This was 
followed by performing antimicrobiological testing using disk diffusion tests on S. 
aureus grown agar plates in order to check the sensitivity of the bacteria using 
these formulations (as explained in Table 1.2). 
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Table 1.2: The table below shows the summarized experimental plan of the 
study present 
Control formulation Drug (CHX) Anti-microbiology 
Testing 
 With Without Agar-Disk diffusion test 
Liposomes        +       -  
 
 
Staphylococcus aureus 
Ethosomes        +       - 
Transfersomes        +       - 
        +       -  
Special formulation  
        
Ultraflexible-nanosized 
lipidic formulation 
(Propanosomes) 
       +       - 
 
1.10 Agar-disk diffusion test  
Agar disk diffusion test is one of the commonly used methods to check the 
bacterial susceptibility. Small filter paper disks (6mm) were impregnated with 
standard amount of antibiotic and placed on to the agar plate on which the bacteria 
have been swabbed. These plates were then incubated for overnight and the zone 
of inhibition was measured. The high susceptibility of the bacteria was indicated 
by larger zone of inhibition, while resistance was indicated by small or no zone of 
inhibition. Figure 1.12 shows a typical example of agar disk diffusion test. 
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Figure 1.12: An example of plate showing disk diffusion study. The 
impregnated disk showing varying degrees of zone of inhibition. The results 
can be by measuring the diameter of each zone of inhibition. 
1.11 Working Hypothesis 
Anti-bacterial formulation with better skin penetration can be delivered as anti-
bacterial drug to either act as bactericidal or bacteriostatic on deep routed S. 
aureus to treat skin infection. This project tests this hypothesis by preparing 
antibacterial formulations to stop the growth of the bacteria. 
1.12 Main aim 
The main aim of this project was to prepare anti-bacterial formulation 
propanosomes for the delivery of the drug to stop the growth of the bacteria. 
1.13 Specific aims of Research 
1. To prepare the control vesicle formulation: namely liposomes, ethosomes, 
transfersomes and optimize its preparatory protocol using thin-film 
hydration method. 
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2. To perform the characterization techniques including size analysis, zeta 
potential measurement and evaluation of the degree of deformability of the 
vesicles. 
3. To design and optimize the novel vesicle formulations of propanosomes. 
4. To perform the anti-bacterial testing using disk diffusion test. 
5. To test the antibacterial property of the control vesicle formulation and 
propanosomes. 
6. To investigate the antibacterial property of chlorhexidine for suppressing 
the growth of the bacteria using propanosome formulations. 
7. To analyse the data by comparing and contrasting the antibacterial 
properties of the vesicles carrying with/without drug on bacteria. 
8. To analyse the data and write up the MSc thesis. 
1.14 Elements of originality 
The novelity of the project is based mainly on the preparation of anti-bacterial 
ultradeformable lipidic vesicles. This is the new concept of the project as there is 
no published research for the use of antibacterial propanosomal formulations for 
the skin treatment. Moreover, this formulation not only provides the anti-bacterial 
activity but also deliver drug chlorhexidine permeating through the skin for killing 
S. aureus. This project has contributed towards the application of nanotechnology 
and it has broadened the scope of liposome applications for treatment of skin 
infections. 
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2 Materials and Methods 
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2.1 Materials 
Soya phosphatidylcholine (SPC; Lipoid S-100) and 1, 2–Dipalmitoyl–sn–glycerol-
3-phodphocholine (DPPC) were purchased from Lipoid GmbH, Switzerland. 
Cholestrol, Tween 80 solution, Span 80, Sodium cholate hydrate, Chlorhexidine 
base, Chlorhexidine diacetate salt hydrate, PBS (Phosphate buffered saline) tablets 
were supplied by Sigma Aldrich, UK. Chloroform (99+%) stabilised with 0.75% 
ethanol, Propan-2-ol (Iso-propyl alcohol), methanol (HPLC grade) and ethanol 
99+% (GLC absolute grade) were all supplied by Fisher Scientific, UK. 
Nutrient agar: 90 mm ready poured plate Oxoid from (Fisher Scientific, UK), 
autoclaved disks, autoclaved 20 microliter pipette tips, Staphylococcus aureus 
(NCIMB6571) culture medium from Microbiology laboratory UCLAN, Spreader 
[inoculating, L-shape, sterile polystyrene inner packs of 5 (80 bags)] were all 
obtained from Fisher Scientific Ltd, UK. The autoclaved distilled water for 
dissolving was obtained from UCLAN research laboratories, chlorhexidine 
diacetate salt was supplied by Sigma Aldrich, UK.   
2.1.1 Equipments  
Malvern Mastersizer 2000 and Malvern Zetasizer (Nano series (Nano 2S) were 
used for size analysis as described in Section 2.1.2 and 2.1.3. The technique of 
lipid extrusion and size reduction of the lipidic particles was also discussed, B chi 
rotavapor from B chi, Switzerland, bath sonicator (Model SC-20) from Fisher 
Scientific, UK, sterile cupboard (Uni Mat-BS class II Microbiological safety), 
vortex mixer from Stuart
®, weighing balance, 2, 20, 200 and 1000 μl pipettes 
(gilson) and pipette tips, forceps, aluminium  foil, 10 ml vials, 100 ml (round 
bottom short neck socket 24/29 100 ml)  flasks, 5 ml volumetric flasks, sterile 
spatula, 10 ml and 5 ml beakers,  pipette adaptors were all obtained from Fisher 
Scientific Ltd, UK and CM 120 Bio Twin transmission electron microscope 
(Philips Electron Optics BV, The Netherlands). 
For the preparation of the lipidic particles, Lipofast Basic and stabiliser 
(Avestin,Inc), Nuclepore polycarbonate Track-Etch Membrane filters with a pore 
size of 12.0, 10.0 , 5.0, 1.0, 2.0, 0.8, 0.2, 0.4 µm  were purchased from Fisher 
Scientific, UK.  
  
38 
2.1.2 Malvern Mastersizer 2000 particle size analyser 
Malvern mastersizer 2000 (Model number: APA2000) was used to measure the 
particle size (0.02 - 2000 µm). This model analysed the samples based on two 
theories, firstly by Fraunhofer model (Mastersizer user Manual, 2007) stated that a 
scattering pattern was created when a solid, opaque disc of known size was passed 
through beam of light. This model did satisfy few particles but was not meant for 
all particles as very few particles were in disc shaped and others were transparent. 
Hence, the instrument also employed Mie theory which assumed that the amount 
of light passed through a particle was directly proportional to the light passed 
through or directly absorbed (Mastersizer 2000 user manual, 2007).  
2.1.3 Zeta potential using Malvern Zetasizer Nano 2S 
Malvern Zeta Nano (Nano series; Nano 2S) measured the particle zeta potential, 
size and molecular weight. The system also had the ability to perform autotitration 
measurements and trend measurements including the determination of protein 
melting point. Zeta potential was measured by determination of how fast the 
particles could move in liquid when an electrical field was applied i.e. velocity. 
This was relevant for the investigation when a certain range of particle size was 
desirable. (Zeta size user Mannual, 2007). The Zeta size analyser was used to 
check the zeta potential (mV) of the formulations by pipetting 800 µl of the 
sample into the zeta sizer cuvette which was then loaded into the machine. The 
system was allowed to calibrate for 2 minutes and the results were recorded in 
triplicates with 10 measurements for each experiment. 
2.1.4 Preparation of thin lipid films using rotary evaporation 
The rotary evaporator was used to remove the solvents from the mixture of 
solvents from the flask which was attached to the condenser under reduced 
pressure. The machine utilized the lower pressure than the atmospheric pressure 
which allowed the solvents to evaporate at a lower temperature. Furthermore, the 
rotation increased the surface area and therefore evaporation was facilitated. 
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2.1.5 Bath sonication 
Bath sonicator depended on applying ultrasound energy on the sample, possibly 
resulting in size reduction of particles. The bath sonicator was operated as 
follows:- 
 The plan object was placed onto the secondary holding container. The cleaning 
solution was poured into the secondary container in order to completely submerge 
the object. 
1) The secondary holding container was placed into the empty ultrasonic 
cleaner. The deionized water was poured into the ultrasonic cleaner 
until the water was half way up the side of the secondary container. 
2) The desired time was set up on the ultrasonic bath. 
2.1.6 Transmission Electron Microscopy (TEM) 
The suspension sample was deposited on carbon-coated copper grids (400 mesh) 
and negatively stained with phosphotungstic acid (1% w/v). The sample was 
viewed using CM 120 Bio Twin transmission electron microscope (Philips 
Electron Optics BV, The netherlands). This method was adapted from that used by 
Elhissi and co-workers (2007). 
2.1.7 Lipid Extrusion 
Extrusion was used to reduce particle size and determine the flexibility of the 
formulations. This was performed repeatedly through the polycarbonate membrane 
filter pore. Depending on the formulations, 11 to 21 passes were sufficient to 
produce a uniform suspension formulation of the desire size, similar to the 
procedure previously employed for the preparation of large unilamellar vesicles 
(MacDonald, 1991) using a LiposoFast
TM
 mini-extruder. 
2.1.8 Degree of deformability using lipid extruder 
For the comparative measurements of elasticity of the bilayer of liposomes, 
ethosomes, transfersomes and propanosomes a lipid extruder was used to carry out 
the extrusion measurements (Bergh et al., 2001).  At a constant pressure the 
vesicles were extruded through polycarbonate filter with defined pore size 
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(Nucleopore). The vesicular elasticity was expressed in terms of deformability 
index (D) which was proportional to j (rv/ rp)
2
 where, ‗j‘ is the weight of the 
suspension, which was extruded for a specific time through a polycarbonate filter 
of defined pore size, ‗rv‘ the size of the vesicle and ‗rp‘ the pore  size of the vesicle 
membrane (Gupta et al., 2005). 
2.2 Method and procedure used for vesicular preparation 
The diagram below outlined the methods employed for producing a range of 
formulations such as liposomes, transferosomes, ethosomes and propanosomes 
(Figure 2.1).  The thin film hydration method was used for the preparation of these 
formulations. 
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Figure 2.1: Flow diagram showing the different methods employed in the 
study to prepare a range of formulations. 
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2.3 General procedure for preparation of formulations 
All the formulations were prepared using thin film hydration technique. The 
phospholipid and cholesterol or phospholipid and surfactant were taken at a 
specific molar ratio or weight ratio, respectively in a round bottom flask. The 
desire mixture was dissolved in chloroform. For drug loaded formulations CHX 
base was added at this stage. The flask was then attached to rotary evaporator 
above the transition temperature of the lipid. The rotary evaporator was allowed to 
rotate at a speed of 280 rpm under a vacuum at 23 mbar for 60 minutes. A thin 
lipid film was obtained after 60 minutes. Then the vacuum pump was turned off to 
release the negative pressure and the flask was detached. The film was then 
hydrated either with distil water, PBS (7.4), water + ethanol mixture or 0.9% NaCl 
solution + propan2-ol mixture as to prepare the desire formulation. The resulting 
formulation was mixed manually by vigorous shaking and vortexing at 1800 rpm 
for 15 minutes. The flask was then kept for annealing for one hour or for rotation 
as per the desire formulation to be prepared. The annealing was performed to 
stabilise the bilayer membrane. The resultant formulation was then checked for 
further particle analysis using various techniques. The procedures of all the 
vesicular formulations are summerised in Table 2.1. 
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Table 2.1: A summery explaining the prepration of vesiclular formulations 
Formulations Compositions of the 
ingredients 
Condition of the rotatory 
evaporator and hydration of the 
formulation 
Liposomes SPC: Chol (1:1) molar ratio  
DPPC : Chol (70:30) weight 
ratio 
 Hydration with distilled 
water 
 1 hour stable  annealing 
Ethosomes SPC: Chol (1:1) molar ratio  
 
 One step hydration 
 Two step hydration 
 Hydration with water + 
ethanol mixture 
  1 hour stable annealing 
Transfersomes SPC: Surfactant (85: 15) (w/w)  Hydration with PBS (7.4) 
solvent 
 2 hours rotation in rotatory 
evaporator 
Propanosomes SPC: Surfactant (85: 15) (w/w)  Hydration with 0.9% NaCl 
solution + propan-2-ol 
mixture 
 1 hour stable annealing 
 30 minutes bath sonication 
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2.2.1 Bacterial sensitivity test 
Bacterial sensitivity towards the formulations was investigated using the agar disk 
diffusion test.  
1) Agar Disk Diffusion Test 
A culture of Staphylococcus aureus (NCIMB 6571) was prepared in a nutrient 
broth by aseptically diluting 0.1 ml of the culture into 9 ml of fresh nutrient broth 
followed by thorough mixing. The bacteria were spreaded in plates by using 0.1 
ml of inoculum over the nutrient agar surface followed by incubation for one day 
to produce of a confluent lawn of bacteria on the agar medium. A swab was 
dipped into the culture medium and then it was dispersed onto the nutrient agar. 
This was passed three times over the same area to make sure it was fully covered. 
The forceps tip was sterilized by passing it three times on a Bunsen burner. Then, 
the sterile filter paper disk was picked up with the sterile forceps and was placed 
onto the disk of the agar medium. The lipid formulation (2 µl) was pipetted onto 
the disk area. The plate was covered with the lid and sealed with Paraflim. The 
plates were inverted and incubated at 37ºC for 18-24 hours. 
The bacterial sensitivity was processed over three day‘s process involving:- 
 Inoculation of the nutrient broth which was done on day 1, 
 Disk diffusion test was performed on day 2 and 
 Observation of the results on day 3 
On day one, a drop of S. aureus (NCIMB 6571) was added to the broth of 
nutrients inside the incubator. A clean environment was essential so ethanol was 
used to clean the hood and areas where tests were performed. The inoculated tubes 
were placed into an orbital shaker at 36°C overnight using 1800 rpm setting. On 
day two, the inoculated tube was removed and cultured with 100 µl of S. aureus 
and then 100 µl cultured nutrient added to the agar plates. On day three, the 
cultured nutrients were spread and kept for 10 minutes and then autoclaved disks 
on each of the plates and lipid formulations added.  
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Figure 2.2: A flow diagram showing the disk diffusion testing procedure 
carried out for the lipidic samples. 
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2.2.2 Storage of the formulations 
 All the above formulations were transferred into the vial covered with 
aluminium foil to protect it from light and this was kept in the refrigerator 
at 4 ºC subsequently. 
2.2.3 Statistical analysis 
 
The statistical analysis was performed by taking the means and SDs for all the 
samples. The optimized experiments were undertaken in duplicate. No student‘s t-
test or similar statistical test was employed in the study due to time constain in 
doing serval experiments. 
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3 Results 
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3.1 Formulation optimising using lipid extruder 
Figure 3.1 illustrates size analysis of the samples using a Malvern Mastersizer 
instrument to determine the span and size of the in various formulations.  
 
 
 
Figure 3.1: A typical bell shape for size distribution of particles in liposomal 
sample prior to extrusion. 
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3.2 Optimised  vesicular formulations  
In this section, the experiments performed in the developmental part (not shown) 
of the study were optimised to perform the experiments and the final conclusions 
were drawn based on these optimised results. It is also important to bear in mind, 
that laser diffraction (Malvern Mastersizer) was employed for measurement of 
particles having size of 1 µm or above. In this case, the term used to express the 
polydispersity was ―Span‖. By contrast, for particles expected to have size below 1 
µm, dynamic light scattering was employed (using Zetasizer Nanoseries) for most 
accurate measurements. Hence, it was not possible to compare the polydispersity 
of micro-sized particles with nano-sized particles. 
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Figure 3.2 shows the zeta potential of both L and DLL formulations. The results 
showed that the surface charge (i.e. zeta potential) values of empty liposomes were 
slightly negative and unaffected by extrusion. Inclusion of the drug has reversed 
the charge of vesicles in a way that was dependent on the size of the membrane 
pores (Figure 3.2).  
 
 
 
Figure 3.2: Bar chart showing the zeta potential of empty liposomes (L) and 
drug-loaded liposomes (DLL) following extrusion through membrane filters 
with different pore sizes (5, 2 and 1 µm).  The Drug-loaded liposomes did not 
passed through the 1µm filters as the desire size was obtained in 2 µm 
polycarbonate membrane filters. The liposomes were prepared using SPC 
and cholesterol (1:1 molar ratio). The results represent the mean (±SEM) of 2 
experiments (n=2). 
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Figure 3.3 clearly shows that there was a marked decrease in the mean size of 
liposomes with extrusion, regardless of drug inclusion. However, drug-loaded 
liposomes are always smaller than empty liposomes. Also, it was not possible to 
extrude drug-loaded vesicles through the 1 µm polycarbonate filters, suggesting 
interaction of the drug with the liposomal bilayers in a manner than affected 
vesicle size and bilayer rigidity.  
 
 
 
Figure 3.3:  Bar chart showing the size of empty liposomes (L) and drug-
loaded liposomes (DLL) following extrusion through membrane filters with 
different pore sizes (5, 2, 1 µm). The drug loaded liposomes did not pass 
through the 1 µm membrane filters as the desire size was obtained in 2 µm 
membrane filters. The liposomes were prepared using SPC and cholesterol 
(1:1 molar ratio). The results represent the mean (±SEM) of two experiments 
(n=2). 
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Figure 3.4 shows the relationship between Span and extrusion for L and DLL.  
Drug inclusion in the liposomal formulation caused a decrease in polydispersity of 
the extruded vesicles, suggesting the presence of chlorhexidine may enhance 
liposome dispersion properties by reducing the aggregation of the vesicles. This 
correlates well with the reduced vesicle size in formulations that included the drug 
(Figure 3.3). 
 
 
 
Figure 3.4: Bar charts showing the span for empty liposomes (L) and drug-
loaded liposomes (DLL) following extrusion through membrane filters with 
different pore sizes (5,  2, 1 µm). The drug loaded liposomes did not pass 
through the 1 µm membrane filters as the desire size was obtained in 2 µm 
membrane filters. The liposomes were prepared using SPC and cholesterol 
(1:1 molar ratio). The results represent the mean (±SEM) of two experiments 
(n=2). 
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Figure 3.5 demonstrated that the zeta potential of both E and DLE were positive in 
ethosomes.  The zeta potential values increased with drug incorporation into the 
formulations, again confirming that this drug changed the properties of lipid 
bilayers. 
 
 
 
 
 
Figure 3.5: Bar charts showing zeta potential for empty ethosomes (E) and 
drug loaded ethosomes (DLL) following extrusion through membrane filters 
with different pore sizes (10, 5, 2 µm). The ethosomes were prepared using 
SPC and cholesterol (1:1 molar ratio).The results represent the mean (±SEM) 
of two experiments (n=2). 
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In figure 3.6, the results shows that the mean particle size of ethosomes 
considering extrusion and drug incorporation the data reveal that extrusion did not 
affect the size of ethosomes and the drug increased the size of vesicles 
independently of extrusion. This indicates the deformability of ethosomes; hence 
extrusion did not reduce the size of vesicles. Also, the drug did not affect the 
vesicle deformability and flexibility.  This so far shows that shear-responsiveness 
of ethosomes is different from that of liposomes.  
 
 
 
Figure 3.6: Bar charts showing mean particle sizes for empty ethosomes (E) 
and drug loaded ethosomes (DLL) following extrusion through membrane 
filters with different pore sizes (10, 5, 2 µm). The ethosomes were prepared 
using SPC and cholesterol (1:1 molar ratio). The results represent the mean 
(±SEM) of two experiments (n=2). 
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The polydispersity of ethosomes, as a result of drug inclusion and extrusion, is 
very difficult to interpret (Figure 3.7). For empty ethosomes, the effect of 
extrusion on polydispersity was mild. By contrast, for drug-included ethosomes, 
the polydispersity was high prior to extrusion, decreased upon extrusion through 
10 µm and 5 µm filters and partially regained its high polydispersity when 
extruded through the 2µm filters (Figure 3.7).  These findings indicate aggregation 
of drug containing ethosomes only when high shear was applied such as that 
provided using the small (2 µm) polycarbonate membrane filters. Further 
investigations are needed to understand the manners of interaction between 
chlorhexidine and ethosomal bilayers.   
 
 
 
Figure 3.7: Bar charts showing span for empty ethosomes (E) and drug 
loaded ethosomes (DLL) following extrusion through membrane filters with 
different pore sizes (10, 5, 2 µm). The ethosomes were prepared using SPC 
and cholesterol (1:1 molar ratio). The results represent the mean (±SEM) of 
two experiments (n=2). 
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For transferosmal formulations, the zeta potential ranged from slightly negative to 
slightly positive when no drug was included (Figure 3.8). However, upon 
incorporation of the drug, all formulations had positive zeta potential 
measurements, suggesting the interaction of the drug with the transferosomal 
bilayers. The effect of extrusion on the zeta potential of transferosomes was small. 
 
 
 
Figure 3.8: Bar charts showing zeta potential for empty transfersomes using 
Tween 80 (TF-TW) and drug loaded trasnfersomes using Tween 80 (DTF-
TW) following extrusion through membrane filters with different pore sizes 
(2, 1, 0.8 and sandwich between 0.2-0.4 µm). The transfersomes were 
prepared using SPC and Tween 80 surfactant (85: 15) % (w/w) weight ratio. 
The results represent the mean  (±SEM) of two experiments (n=2). 
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Unlike ethosomes which showed high ultradeformability with no major change in 
size upon extrusion (Figure 3.6), transferosomes underwent size reduction upon 
extrusion and tended to have the size of the filter pores through which they were 
extruded (Figure 3.9). Also, in general, drug did not affect the size of 
transferosomes (Figure 3.9) although it increased the zeta potential (Figure 3.8).  
 
 
 
Figure 3.9: Bar charts showing mean particle sizes for empty transfersomes 
using Tween 80 (TF-TW) and drug loaded trasnfersomes using Tween 80 
(DTF-TW) following extrusion through membrane filters with different pore 
sizes (2, 1, 0.8 and sandwich between 0.2-0.4 µm). The transfersomes were 
prepared using SPC and Tween 80 surfactant (85: 15) % (w/w) weight ratio.  
The results represent the mean (±SEM) of two experiments (n=2). 
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Figure 3.10 exhibits the polydispersity of both TF-TW and DTF-TW of crude and 
vesicles extruded through 2, 1, 0.8 and (0.2-0.4) µm filters. The results showed 
that the polydispersity markedly decreased by extrusion of the crude vesicles 
through 2 µm and 1 µm membrane filters, regardless of the presence of 
chlorhexidine. The same observation was seen when the 0.8 µm extruded vesicles 
were further pushed through the 0.2-0.4 µm filters, indicating the fragmentation of 
vesicles upon shearing. Both the TF-TW and DTF-TW were similar in 
polydispersity, indicating that addition of drug was not responsible for size 
distribution changes. 
 
 
Figure 3.10: Bar charts showing polydispersity for empty transfersomes using 
Tween 80 (TF-TW) and drug loaded trasnfersomes using Tween 80 (DTF-
TW) following extrusion through membrane filters with different pore sizes 
(2, 1, 0.8 and sandwich between 0.2-0.4 µm). The transfersomes were 
prepared using SPC and Tween 80 surfactant (85: 15) % (w/w) weight ratio.  
The results represent the mean (±SEM) of two experiments (n=2).  
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Figure 3.11 shows the zeta potential of both TF-SP and DTF-SP of crude and 
vesicles extruded through 2 µm, 1 µm, 0.8 µm and 0.2-0.4 µm membrane filters.   
The empty trasnfersomes had slightly negative zeta potential, whilst drug-loaded 
transferosomes had slightly positive zeta potential values, indicating that surface 
charge of the vesicles was reversed upon incorporation of the drug, again 
confirming the interaction of this drug with the lipid bilayers of vesicles. 
 
 
 
 
Figure 3.11: Bar charts showing zeta potential for empty transfersomes using 
Span 80 (TF-SP) and drug loaded trasnfersomes using Span 80 (DTF-SP) 
following extrusion through membrane filters with different pore sizes (2, 1, 
0.8 and sandwich between 0.2-0.4 µm). The transfersomes were prepared 
using SPC and Span 80 surfactant (85: 15) % (w/w) weight ratio.  The results 
represent the mean (±SEM) of two experiments (n=2). 
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The Figure 3.12 demonstrates that extrusion resulted in size reduction of the 
vesicles. Also, incorporation of the drug had no effect on the size of extruded or 
unextruded transferosomes. Size reduction of transferosomes upon extrusion was 
consistent with the findings seen earlier with liposomes (Figure 3.3), however for 
liposomes the drug tended to reduce vesicle size whilst with transferosomes no 
effect of the drug on particle size was seen (Figure 3.12).  
 
 
 
Figure 3.12: Bar charts showing mean particle sizes for empty transfersomes 
using Span 80 (TF-SP) and drug loaded trasnfersomes using Span 80 (DTF-
SP) following extrusion through membrane filters with different pore sizes (2, 
1, 0.8 and sandwich between 0.2-0.4 µm). The transfersomes were prepared 
using SPC and Span 80 surfactant (85: 15) % (w/w) weight ratio. The results 
represent the mean (±SEM) of two experiments (n=2).  
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Figure 3.13 shows that the polydispersity of both TF-SP and DTF-SP of crude and 
extruded vesicles 2, 1, 0.8, (0.2-0.4) µm PMFP. The results show that the 
polydispersity markedly decreased upon extrusion in both TF-SP and DTF-SP. 
However, polydispersity of the particles in DTF-SP was observed to be higher 
than that of TF-SP. These results clearly indicate that the addition of drug is 
responsible for the change in polydispersity of the vesicles. It is worth mentioning 
that whilst median size was unaffected by drug inclusion (Figure 3.12), the drug 
increased the presence of relatively small and large vesicles in the sample, hence 
broadening the size distribution (i.e. increasing polydispersity). 
 
 
 
Figure 3.13: Bar charts showing polydispersity for empty transfersomes using 
Span 80 (TF-SP) and drug loaded trasnfersomes using Span 80 (DTF-SP) 
following extrusion through membrane filters with different pore sizes (2, 1, 
0.8 and sandwich between 0.2-0.4 µm). The transfersomes were prepared 
using SPC and Span 80 surfactant (85: 15) % (w/w) weight ratio. The results 
represent the mean (±SEM) of two experiments (n=2).  
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Figure 3.14,  shows that zeta potential using TF-SCH and DTF-SCH formulations 
was independent of extrusion and drug inclusion; using SCH in transferosomes 
showed positive zeta potential values which were also unaffected by incoprpration 
of the drug (Figure 3.14). Hence, zeta potential was dependent on lipid phase 
composition such as the presence/absence of chlorhexidine and certain surfactants 
and deformability enhancers (e.g. edge activators).  
 
  
Figure 3.14: Bar charts showing zeta potential for empty transfersomes using 
sodium cholate hydrate (TF-SCH) and drug loaded trasnfersomes using 
sodium cholate hyrate (DTF-SCH) following extrusion through membrane 
filters with different pore sizes (2, 1, 0.8 and sandwich between 0.2-0.4 µm). 
The transfersomes were prepared using SPC and Sodium cholate hydrate 
surfactant (85: 15) % (w/w) weight ratio. The results represent the mean 
(±SEM) of two experiments (n=2).   
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Although the effect of drug on zeta potential of SCH transferosomes was mild 
(Figure 3.14), the drug tended to generate larger transferosomes compared to the 
corresponding drug-free formulations (Figure 3.15). For both drug-free and drug-
containing formulations, the transferosome size was reduced by extrusion. The 
particle size measurements were larger in DTF-SCH compared to TF-SCH. This 
shows that addition of the drug was responsible for the increase in particle size of 
the SCH transferosomes (Figure 3.15). 
 
 
Figure 3.15: Bar charts showing mean particle sizes for empty transfersomes 
using SCH (TF-SCH) and drug loaded trasnfersomes using SCH (DTF-SCH) 
following extrusion through membrane filters with different pore sizes (2, 1, 
0.8 and sandwich between 0.2-0.4 µm). The transfersomes were prepared 
using SPC and Sodium cholate hydrate surfactant (85: 15) % (w/w) weight 
ratio. The results represent the mean (±SEM) of two experiments (n=2).   
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Figure 3.16 indicates that the polydispersity of both TF-SCH and DTF-SCH of 
crude and 2 µm, 1 µm, 0.8 µm, 0.2-0.4 µm PMFP was progressively reduced by 
extrusion, and there was no effect of the drug on the vesicle polydispersity, except 
for the 1 µm extruded vesicles which demonstrated an increase in vesicle 
polydispersity as a result of drug incorporation. Further studies are needed to 
understand the reason behind the different behaviour of this particular formulation.  
 
 
 
Figure 3.16: Bar charts showing polydispersity for empty transfersomes using 
SCH (TF-SCH) and drug loaded trasnfersomes using SCH (DTF-SCH) 
following extrusion through membrane filters with different pore sizes (2, 1, 
0.8 and sandwich between 0.2-0.4 µm). The transfersomes were prepared 
using SPC and Sodium cholate hydrate surfactant (85: 15) % (w/w) weight 
ratio. The results represent the mean (±SEM)  of two experiments (n=2).   
 
 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
Crude 2 µm (5 times) 1 µm (5 times) 0.8 µm (3
times)
(0.2-0.4) µm
(21 times)
P
o
ly
d
is
p
er
si
ty
 
Transfersomal formulations (SCH) 
TF- SCH
DTF-SCH
  
65 
The Figure 3.17 demonstrates the zeta potential measurements of propoanosomes 
unextruded and those extruded through successive polycarbonate membrane filters 
(2, 1, 0.8, 0.2-0.4 µm). For empty formulations, the zeta potential was slightly 
negative. The inclusion of drug has demonstrated capability to make the zeta 
potential positive, suggesting an interaction between chlorhexidine and 
propanosomal bilayers.  Interestingly, in the drug-containing formulations also 
shown a trend of an increase in zeta potential was observed when the vesicles were 
extruded through the smaller pores. This might be attributed to the enhanced 
interaction between the drug and the bilayers owing to the increased surface area 
of the lipid following extrusion.  
 
 
Figure 3.17: Bar charts showing zeta potential for empty propansomes using 
(P) and drug loaded propansomes (DLP) following extrusion through 
membrane filters with different pore sizes (2, 1, 0.8 and sandwich between 
0.2-0.4 µm). The transfersomes were prepared using SPC and Span 80 (85: 
15) % (w/w) weight ratio. The results represent the mean (±SEM)  of two 
experiments (n=2).   
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Figure 3.18 shows the particle size of both P and DLP of crude and vesicles 
extruded through 2, 1, 0.8, 0.2-0.4 µm PMFP. The result shows that the size 
markedly decreased by extrusion, and there was no effect of the drug on the size of 
propanosomes.  
 
 
 
Figure 3.18: Bar charts showing mean particle size for empty propansomes 
using (P) and drug loaded propansomes (DLP) following extrusion through 
membrane filters with different pore sizes (2, 1, 0.8 and sandwich between 
0.2-0.4 µm). The transfersomes were prepared using SPC and Span 80 
surfactant (85: 15) % (w/w) weight ratio. The results represent the mean 
(±SEM) of two experiments (n=2).   
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Figure 3.19 shows the polydispersity of propanosomes to be minimally dependent 
on formulation, considering the Span measurements for the crude vesicles and 
vesicles extruded through 2 µm and 1 µm filters, and the PDI values for the 
formulations extruded through 0.8 µm, and 0.2-0.4 µm filters. 
 
 
 
Figure 3.19: Bar charts showing polydispersity for empty propansomes using 
(P) and drug loaded propansomes (DLP) following extrusion through 
membrane filters with different pore sizes (2, 1, 0.8 and sandwich between 
0.2-0.4 µm). The transfersomes were prepared using SPC and Span 80 
surfactant (85: 15) % (w/w) weight ratio. The results represent the mean  
(±SEM) of two experiments (n=2).   
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3.2.1 Degree of Deformability (D) testing Results 
In all the below results presented below, the mean of (0.2- 0.4) µm PMFP was 
taken as 0.3 µm for calculation of D for trasnfersomal and propanosomal 
formulations. 
In Figure 3.20, while passing the liposomes from crude to 5 µm PMFP, a lot of 
pressure was required to pass them through the membrane as the size of the 
liposomes in the crude stage was large as 7 µm (results not shown). For DLL the 
formulation was not allowed to pass through 1 µm PMFP as the desire size of the 
vesicles were obtained at 2 µm PMFP stage. The degree of deformability for 
empty liposomes shows inconsistency through progressive extrusion. However, 
for drug-loaded liposomes the D is decreasing through extrusion. 
 
 
 
Figure 3.20: Bar charts showing degree of deformability of empty liposomes 
(L) and drug-loaded liposomes (DLL) following extrusion through membrane 
filters with different pore sizes 5µm, 2 µm and 1 µm. The results represent the 
mean (±SEM) of two experiments (n= 2).  
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As shown in Figure 3.21, throughout the whole procedure of extrusion, ethosomes 
were hard to extrude due to their large particle size while passing from crude to 5 
µm PMFP. The degree of deformability for E and DLE are the same through 
progressive extrusion. However, for DLE there is marked increase in D due to 
aggregation of the particles. 
 
 
 
 
Figure 3.21: Bar charts showing degree of deformability for empty ethosomes 
(E) and drug-loaded ethosomes (DLE) following extrusion through 
membrane filters with different pore sizes 10 µm, 5 µm and 2 µm. The results 
represent the mean  (±SEM) of two experiments (n= 2). 
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As shown in Figure 3.22, the transfersomal formulations were smoothly extruded 
through all the PMFP. However, while passing through 1 µm to 0.8 µm PMFP 
slightly back pressure of the sample was observed. A marked decreased in D for 
both TF-TW and DTF-TW could be observed thorugh progressive extrusion. 
 
 
 
Figure 3.22: Bar charts showing degree of deformability for empty 
trasnfersomes using Tween 80 (TW) and drug-loaded transfersomes  using 
Tween 80(DTF-TW) following extrusion through membrane filters with 
different pore sizes 2 µm, 1 µm, 0.8 µm and 0.3 µm. The results represent the 
mean (±SEM) of two experiments (n= 2). 
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In Figure 3.23, the results show that the transfersomal formulations were smoothly 
extruded through all the PMFP. A marked decreased in degree of deformability for 
both TF-SP and DTF-SP could be observed through progressive extrusion. 
 
 
 
 
Figure 3.23: Bar charts showing degree of deformability of empty 
trasnfersomes using Span 80 (SP) and drug-loaded transfersomes  using Span 
80(DTF-SP) following extrusion through membrane filters with different pore 
sizes 2 µm, 1 µm, 0.8 µm and 0.3 µm. The results represent the mean (±SEM)  
of two experiments (n= 2). 
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As illustrated in Figure 3.24, the transfersomal formulations were smoothly 
extruded through all the PMFP. However, while passing through 2 µm to 1 µm 
PMFP slightly back-pressure of the sample was observed. A marked decreased in 
D for both TF-SCH and DTF-SCH could be observed thorugh progressive 
extrusion. 
 
 
 
 
Figure 3.24: Bar charts showing degree of deformability of empty 
trasnfersomes using Sodium cholate hydrate (SCH) and drug-loaded 
transfersomes using Sodium cholate hydrate (DTF-SCH) following extrusion 
through membrane filters with different pore sizes 2 µm, 1 µm, 0.8 µm and 
0.3 µm. The results represent the mean (±SEM)  of two experiments (n= 2). 
 
 
-10
-5
0
5
10
15
20
25
30
35
40
2 µm 1 µm  0.8 µm 0.3 µm
D
eg
re
e 
o
f 
D
ef
o
rm
a
b
il
it
y
  
(D
) 
 
Transfersomal Formulations (SCH) 
 
TF-SCH
DTF-SCH
  
73 
As revealed in Figure 3.25, the propanosomal formulations were smoothly 
extruded through all the PMFP. However, while passing through 2 µm to 1 µm 
PMFP, the sample look more diluted. A marked decreased in D for both P and 
DLP could be observed through progressive extrusion. 
 
 
 
 
Figure 3.25: Bar charts showing degree of deformability of empty 
propansomes and drug-loaded propanosomes (DLP) following extrusion 
through membrane filters with different pore sizes 2 µm, 1 µm, 0.8 µm and 
0.3 µm. The results represent the mean (±SEM)  of two experiments (n= 2). 
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3.2.2 Disk diffusion testing  
Agar disk diffusion testing was performed by addition of 2 µl of the formulations 
within the respective disks. The formulation treated disks were then impregnanted 
into the agar plates containing confluence of bacteria. The analyses of the disks 
were performed by overnight incubation at 37 ˚C for 18-24 hours in the incubator. 
The susceptibility of the bacteria towards the formulations was checked by 
measuring the zone of inhibition. A typical example showing the sample, which 
was added on the impregnated disk, contains 2 µl of chlorhexidine diacetate salt 
hydrates (15 mg/ml) testing, which is exhibiting the zone of inhibition (see Figure 
3.26). 
  
 
 
Figure 3.26: A photograph showing the plate exhibiting the measuring zone of 
inhibition (1.8 cm). The light grey shading represents a conflue of bacteria 
and the dark grey region represents no growth of the test bacteria (n=1). 
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Table 3.1 illustrates that none of the fomulations exhibited any zone of inhibition 
indicating that the bacteria showing no sensitivity in response to formulations. The 
only disk shown the zone of inhibition was the disk impregnanted with the solvent 
containing CHX diacetate salt hydrate. These results atleast revealed that the drug 
can be used against the bacteria. 
Table 3.1: Table showing responses towards agar disk diffusion tests 
performed using various formulations and solvents. 
 
Sr. 
No. 
Formulations (Abbrevations) Zone of inhibition 
(cm) 
Total number of 
experiment 
performed (n) 
01 L - 2 
02 TF-SCH - 2 
03 DTF-SCH - 2 
04 TF-S80 - 2 
05 DTF-S80 - 2 
06 TF-TW - 2 
07 DTF-TW - 2 
08 E - 2 
09 DLE - 2 
10 P (20%) v/v - 2 
11 DLP (20%) v/v - 2 
12 P (40 %) v/v - 2 
13 DLP (40%) v/v - 2 
14 Solvent containing 40% ethanol-
water mixture 
- 2 
15 Solvent containing 70% ethanol-
water mixture 
- 2 
16 Solvent containing 20% propanol+ 
0.9% NaCl mixture 
- 2 
17 Solvent containing 40% propanol+ 
0.9% NaCl mixture 
- 2 
18 Solvent containing 70% propanol+ 
0.9% NaCl mixture 
- 2 
19 CHX diacetate salt hydrate (15 
mg/ml) 
1.4 1 
 
1.8 
1 
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3.2.3 TEM Results 
Figure 3.27 illustrates the structure of propanosomes prepared using SPC asn Span 
80 surfactant. The picture indicted the unilamellar shape of vesicles. 
 
 
 
Figure 3.27: Transmission electron micrograph of propanosomes prepared 
using 20% propanol. This micrograph is typical of 2-3 such different 
experiments.  
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Figure 3.28 illustrates the structure of drug-loaded propanosomes. It indicates the 
disruption in the bilayer of popanosomes. It showed that after adding the drug the 
membrane got disrupted although the concentration of the drug remained low in 
the formulation. 
 
 
 
Figure 3.28: Transmission electron micrograph of drug loaded propanosomes 
prepared using 20% propanol. This micrograph is typical of 2-3 such 
different experiments.  
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Figure 3.29 illustrates the structure of drug-free propanosomes prepared using 40 
% (p/v) propan-2-ol which imparted a membrane disrupting effect in 
propanosomes. 
 
 
 
Figure 3.29: Transmission electron micrograph of empty propanosomes using 
40 % (p/v) propan-2-ol. The picture was taken at 100 nm magnification. This 
micrograph is typical of 2-3 such different experiments.  
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4 Discussion 
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4.1 Reasoning for optimised results 
During the course of experiments all formulations were prepared using thin-film 
hydration method. This method yields heterogeneous sized population of MLVs 
over 1 µm in diameter. Further extrusion technique was employed to achieve a 
homogenous population of formulation of the desired size. The size and zeta 
potential of the formulations were then analyzed (Doherty, 2004). 
The optimised results consisted of data obtained from particle size analysis which 
includes, size and size distribution (Span or PDI) and from zeta potential 
measurements. While laser diffraction was used to measure the size that is 
expected to be 1 µm or larger and dynamic light scattering was employed to 
measure the size of particles in the sub-micron range. As reported by McConnell 
(1991), liposomes made from unsaturated phospholipids (such as SPC) have high 
fluidity when compared to saturated phospholipids and they spread more rapidly at 
the air/ liquid interface due to their low phase transition, and is expected to be 
adsorbed on the W/O interface rapidly (Wang et al., 2011). 
The crude heterogeneous populations of formulations were then allowed for sizing 
for homogeneous distribution within a certain size range. The sizings of the 
liposomes were performed by sequential extrusion at relative low pressure using 
polycarbonate membrane filter pores. It is necessary to seal the membrane holder 
tight to avoid any possible leakage during extrusion of liposomes (Olson, et al., 
1979). In the drug-loaded formulations chlorohexidine base was added in the 
solvent of the lipid phase, as it is a lipophilic in nature, hence was able to easily 
dissolve with the lipids. 
Chlorhexidine base, 1,6-di-(4-chlorophenyldiguanido) hexane is a white crystaline 
solid (m.p. 132 ºC, mw 505.5) (Figure 1.13). CHX base and its salts are widely 
used as antiseptics and disinfectants in pharmaceutical and cosmetic formulations 
(Wade et al., 1994). Previous studies have shown that encapsulation of CHX base 
proven to be more effective against several bacteria when released into the target 
site. Furthermore, studies have shown that sustain release of base enhances drug 
delivery by mediating a more direct and prolonged contact between the carrier and 
the bacteria, skin surface and skin follicles are shown to present a prolonged ex-
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vivo topical antimicrobial activity against Staphylococcus epidermidis. The in-vivo 
studies may confirm these findings (Lboutounne et al., 2002). 
For optimised results SPC was used over DPPC for the preparation of the 
formulations. The reason for SPC to be chosen over DPPC for performing the 
further experiments was due to its lower transition temperature. Hence, hydration 
and extrusion were performed at room temperature which was highly convenient. 
As DPPC having Tc as 41º C (Szoka & Papahadjopoules, 1980) and SPC having 
Tc of  minus 15º C (O‘Neill and Leopold, 1982), the lower transition temperature 
of SPC offers advantages over higher transition temperature of DPPC as the 
bioactive drugs will be release slowly in DPPC due to its higher transition 
temperature. Also, liposomes made from DPPC were more time consuming to 
prepare and extrude. It has been proven that liposomes with high phase transition 
temperature may release the drug more slowly than liposomes made from lower 
phase transition temperatures (Betz et al., 2005; Mozafari & Mortazavi, 2005). As 
mentioned by El Maghraby et al. (2006), DPPC are rigid in structure due to which 
it would be difficult for them to pass through small PMFP for extrusion. 
Moreover, it was preferred to keep the same phospholipid   for all the formulations 
as SPC to offer higher ultra-deformable properties. 
Figure 3.2 revealed that zeta potential values of empty liposomes were negative 
due to the presence of SPC mixture of lipids; this came in agreement with other 
reports (O‘Neill and Leopold, 1982). Using drug loaded liposomes the zeta 
potential drastically increases to positive values, due to the presence of CHX base 
which is symmetrical molecule with two p-chlorophenyl substituted biguanide 
groups, which provides four sites for protonation (Nishihata et al., 1994). There 
are two pKa values observed for CHX (pKa = 10.3 and pKa = 2.2) and between pH 
4 and 8, the CHX dication is the major species in solution (Hugo et al., 1964). 
Therefore, the CHX dication localized at the nanocapsule-solvent interface would 
confer a positive charge on the colloidal carrier (Lboutounne et al., 2002).  
Interaction of lecithin and cholesterol without non-ionic surfactant exhibited 
negative charge on empty liposomes (Muthprasanna et al., 2010). Addition of 
CHX base within the formulation made the net overall charges of the formulation 
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positive (Lboutounne, et al., 2002). This clearly support the agreement of other 
findings with the findings reported in this project. 
Figure 3.3 showed that progressive extrusion has reduced the size of liposomes 
effectively, regardless of drug inclusion in the formulations. However, the drug 
loaded liposomes were similar or not much different from empty liposomes as the 
added CHX base was of very low concentration (0.02% w/w). The other related 
compound, poly-hexamethylene biguanide (PHMB) shows no interaction with 
neutral PC, but a strong preference for anionic phosphatidylglycerol headgroup 
(Ikeda et al., 1983), which was not used, in the present report. This indicates that if 
concentration within the SPC based formulations was increased, it would expect 
that the liposomal formulation would not be able to encapsulate drug at higher 
concentration. Optimisation of entrapment of the drug should be carried out for 
further experimental analysis. 
When empty liposomes (L) were compared with the drug-loaded liposomes 
(DLL), the span was smaller for DLL (Figure 3.4). This indicates that DLL 
formulations were less polydispersed. The decrease in polydispersity of DLL 
might be attributed to higher zeta potential of these formulations compared to 
empty liposomes resulting in individual repulsion of the vesicles and decrease in 
vesicle aggregation. 
Figure 3.5 showed the positive zeta potential values for ethosome formulations. 
The reason of the positive zeta potential is not clear and needs furture research.  
Figure 3.6 demonstrated that mean size of the ethosomes which was unaffected by 
drug inclusion in the formulations. In the previous studies, it has been shown that 
short chain alcohols may have an effect on the main transition temperature of the 
phospholipid (Rowe, 1983). It had also shown that this interdegetated phase have 
been performed on MLVs preparation. This phase may be present in SUVs and 
extrusion technique plays an important role in determining interdegetation 
(Komatsu et al., 1993). Ethanol seems to change the packing of the bilayer, 
making the lipid bilayers interdegetated and may displace the drug to the outer 
layer of the ethosomes. The small particle size of DLE compared to E may be due 
to the presence of CHX base in the interdegetated bilayers. The similarity in size is 
due to high flexibility of the vesicles because of addition of ethanol as permeation 
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enhancer to promote elasticity of the vesicles. The particle sizes of ethosomes are 
comparatively higher than other formulations due to the presence of ethanol which 
is responsible for large sized vesicles. It also makes the ethosomes deformable 
(Muthprasanna et al., 2010). 
Figure 3.7 showed that for empty crude ethosomal preparation, the polydispersity 
was similar to that of the drug loaded ethosomes. The polydispersity of the 
formulations remained consistent due to the elasticity of the vesicles (seen in 
extrusion through 10 and 5 µm filters) and for 2 µm PMFP, the empty ethosomal 
vesicles were destabilized, possibly resulting in translocation of the drug due to 
excessive extrusion pressure. 
Tween 80 was added in the formulation as edge activator in order to improve the 
elasticity of the vesicles. It is a nonionic surfactant with a large head group 
(containing about 20 polyoxyethylene units) and an HLB value of 15, making it 
miscible in water. Thus, Tween 80 is expected to partition between lipid bilayers 
and aqueous phase (El Maghraby et al., 2004). 
Tween 80 contains the ethylene oxide and a long hydrocarbon chain imparting 
both lipophilic and hydrophilic characteristics to the vesicular formulation. It has 
been reported that Tween 80 may interact with the polar head groups of the lipids 
and the modification of H-bonding and ionic forces may occur (Nokhodchi et al., 
2003). 
The DTF-TW formulations had positive zeta potential values due to presence of 
CHX base whilst TF-TW had negative zeta potential measurements when using 2 
and 1 µm polycarbonate membrane filters (Figure 3.8). The TF-TW formulations 
crude and those extruded through 0.8 µm and 0.2-0.4 µm filters had positive zeta 
potential values (Figure 3.8) which may be due to the presence of Tween 80. The 
present results disagree with Lee et al. (2005) who reported that Tween 80 
transfersomes exhibited a more intense negative zeta potential compared to the 
transferosomes manufactured in this study. However, zeta potential may lead to 
greater repulsion between the bilayers, thus an increase in the size of Tween 80 
containing vesicles could be seen (El Zaafarany et al., 2010). Figure 3.9 
demonstrated a negligible difference in particle size between TF-TW and DTF-
TW. Previous reports have shown homogeneously sized transfersomes following 
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extrusion through polycarbonate membranes (Ita et al., 2007). Due to higher HLB 
value of Tween 80, it may form larger particle size transfersomes compared to 
other surfactants (El Zaafarany et al., 2010). 
In other studies, it has been observed that Tween 80 can lower the affinity for 
lipids so they do not favour lipid vesicle formulation as shown by Muthuprasanna 
et al. (2010). The present results disagree with these represented by  
Muthuprasanna et al. (2010), as the transfersomal formulations using Tween 80 
were successfully produced and moreover, they were reduced in size upon 
extrusion. Difference in findings between different studies might be attributed to 
different formulation conditions. 
Figure 3.10 demonstrated that the transfersomes for both TF-TW and DTF-TW 
were monodispersed, indicating the formulation protocol used in this study offered 
high control over particle size distribution of these vesicles.  Span 80 has the 
shortest hydrophobic hydrocarbon chain and is a nonionic surfactant (Ita et al., 
2007; Wei et al., 2007). It has relatively small head group compared with Tween 
80, as it lacks the polyoxyethylene units. It has higher affinity towards lipids as it 
has lower HLB value of 4.3. It is lipophilic and immiscible with water and thus its 
distribution in lipid is higher than water (El Maghraby et al., 2004).  
Figure 3.11 showed transfersomes formulation attributing overall positive zeta 
potential. The reasons are not clear. The experiment needs future research. 
 In a recent study conducted by Muthprasanna et al., (2010), the surfactants during 
formulation acted as an efficient emulsifing agent resulting in decreasing the 
particle size and promoting vesicle flexibility and penetration ability. This is in 
agreement with the results shown in Figure 3.12 using TF-SP with a particle size 
range of 80-90 nm. This could be due to the influence of Span 80 (oil and water 
emulsifier). Hence, Span 80 is suitable for producing small sized vesicles that are 
capable to pass through PMFP allowing higher drug proportions to be delivered 
(Hobbs et al., 1998; Unezaki et al., 1996). Also, Span 80 has high hydrophobicity, 
which also adds to its advantages.  
The polydispersity was higher in DTF-SP and TF-SP (Figure 3.13). This is due to 
instability of the formulation, which was accompanied by foam formation. As 
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Span 80 is anti-foaming agent, it reduces the surface tension but here addition of 
the drug has caused formation of foam. Foam formation should always be avoided 
because it reduces the uniformity of the formulation (Jin et al., 2008). 
Sodium cholate hydrate is a solubilising agent, which may increase the solubility 
of poorly soluble materials. Based on HLB values, SCH has a value of 16.7, 
revealing its low affinity towards lipids (El Maghraby et al., 2004). Studies have 
shown that anionic surfactants cause greater tissue damage than non-ionic 
surfactants (Som et al., 2012). Hence, SCH was not preferred for further analysis 
of novel lipidic formulations. 
SCH is an anionic surfactant because its hydrophilic moiety bears a negative 
charge (Som et al., 2012). Unexpectedly, Figure 3.14 showed that zeta potential 
values were positive for all formulations including TF-SCH and DTF-SCH. This 
might be attributed to the high hydrophilic properties of SCH; hence it was not 
heavily associated with the lipid bilayers.  
Figure 3.15 demonstrated an interaction of SCH and CHX base might be 
responsible for the larger particle size in the formulation for DTF-SCH that may 
contribute to drug leakage or instability of the bilayer upon inclusion of the drug in 
the formulation. Figure 3.16 showed that the polydispersity was similar for both 
the TF-SCH and DTF-SCH formulations. Previous findings have shown the 
presence of SCH to be responsible for making the particle size distribution more 
uniform (Ping and Jiao, 2000). However, the increase in polydispersity for DTF-
SCH may indicate instability of the formulation, which could be due to excessive 
pressure applied upon extrusion through 1 µm PMFP. 
Propanosomes were prepared by combining the ethosomal and trasnfersomal 
protocol. For enhancing the penetration property, propanol was added for 
improving the flexibility of the membrane bilayers, surfactant Span 80 was added 
in order to make ultra-deformable lipidic formulations. The formulations are 
supposed to serve as anti-bacterial without the drug loaded in the formulation by 
exploiting the antibacterial properties of propanol. The antibacterial susceptibity of 
the formulation was discussed in section 4.3. 
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Figure 3.17 demonstrated a positive surface charge for drug-loaded propanosomes. 
As expected, the drug-loaded formulation contains the CHX base which is 
contributing overall to the yield of a positive charge. The empty propanosomes 
had negative zeta potential measurement, confirming the responsibility of the drug 
for the positive zeta potential. This also clearly reveals the association of the drug 
with the bilayers of the propanosomes. 
Figure 3.18 showed no difference in particle size when empty propanosomes and 
drug-loaded propansomes were compared. The propanosomes had smaller particle 
size as expected for transfersomal formulation, indicating that the formulation was 
flexible enough to pass through PMFP. However, drastic decrease from 1 µm 
PMFP to 0.2-0.4 µm PMFP showed that the formulation possibly became instable 
upon pressure application (e.g. upon extrusion). 
Figure 3.19 showed monodispersed distribution of the particles, however, the 
drug-loaded propanosomes may exhibit instabilities, as the polydispersity was 
inconsistent through progressive extrusion. It is possible that extrusion has caused 
leakage of the drug from the bilayers in the form of crystals. This may contribute 
to the broad size distribution by having propanosomes particles in the nano range 
and drug crystals in the micro range within the same preparation. This agrees with 
light microscopy observation using other hydrophobic drugs (e.g. beclometasone 
dipropionate) in liposome formulations (Batavia et al., 2001). 
4.2 Degree of deformability  
Figure 3.20 represents the degree of deformability (D) study for L and DLL 
showing higher D value compare to other formulations (ethosomes, 
trasnferosomes and propansomes). This is due to higher particle size of liposomes 
compared to other formulations, as the liposomes were more rigid in structure due 
to the presence of cholesterol. However, the passage for liposomes through the 
filter pores was more difficult through the small pores, hence higher pressure was 
required. 
Moreover, ethosomes had extremely low D (Figure 3.21) which could be due to 
the presence of ethanol as a penetration enhancer. The D for ethosomes are same 
  
87 
and low for 10, 5 and 2 µm PMFP passage for E and DLE with an exception for 
increased D using drug loaded ethosomes. This is possibly due to aggregation of 
the particles, which underwent extensive stress due to extrusion. The deformability 
in the transfersomes is influenced by the presence of edge activators that could be 
correlated with the difference in chemical structure of these molecules. 
In previous studies, it has been shown that Tween 80 may confer very high 
deformability on vesicles. This could be due to the higher flexible and non-bulky 
hydrocarbon chain of Tween 80. By studying the findings in Figures 3.22-3.24, the 
same phenomenon could be observed where in the D is decreasing in size in both 
TF-TW and DTF-TW. However, it has been observed that TF-TW had higher D in 
comparison with DTF-TW. This could be due the presence of drug in DTF-TW. 
Also studies showed that Span 80 has lowest deformability, due to their 
hydrophobicity which reduces the formation of transient hydrophilic holes in the 
membrane, hence minimizing the amphiphilic property of the bilayers and 
reducing membrane fluidity (El Zaafarany et al., 2010). The results for the 
experiments in this project (Figures 3.22-3.24) agree with the study conducted by 
El Zaafarany and co-workers (2010). Finally, sodium cholate hydrate containing 
trasnfersomes showed least D compared to Tween 80 and Span 80 containing 
transfersomal formulations. Sodium cholate hydrate has steroid-like-structure 
which are bulkier than the other hydrocarbon chain containing surfactants (El 
Zaafarany et al., 2010).     
The significance of drug release could be explained by variations in molecular 
ordering and deformability caused by edge activator (i.e. the edge activator 
possessing transfersomes shows highest deformability with highest drug release 
and vice-versa (El Zaafarany et al., 2010).               
Figure 3.25 showed inconsistency of the D values of the propanosomal 
formulation regardless of the presence of drug. Further investigations of the 
propanosomal formulation through extrusion are needed for the introduction of a 
convincing justification.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
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4.3 Agar disk diffusion testing 
The number of methicillin-resistant (MR) Staphylococcus aureus and MR 
coagulase negative staphylococci (CoNS) strains has been increasing  (Jain et al., 
2008). Methicillin-resistant Staphylococcus aureus (MRSA) strains have also 
emerged as a frequent cause of community acquired infections (Naimi et al., 
2003). It is also becoming one of the major causes for bacterial infections 
underlying soft tissues of the skin among the patients who are visitors in clinics 
and office-based practices (Nathwani et al., 1998; Tice et al. 1995; Dykhuizen et 
al., 1994). To determine the susceptibility of these bacteria, there are several 
methods such as disk diffusion test that helps in determining the MIC (Minimum 
Inhibitory Concentration). The experiments conducted in this study, MIC testing 
was performed to determine the antimicrobial activity of the formulations against 
the S. aureus bacteria. CHX diacetate salt hydrate is an effective antibacterial drug 
against these bacteria as shown in Figure 3.38. 
 A test for control formulations, i.e. liposomes, transfersomes with sodium cholate 
hydrate, transfersomes with sodium cholate and transfersomes with Tween 80 
were individually added on the impregnated disks. It could be seen that the disk 
result shows that these control formulations did not show any zone of inhibition 
around the disk. The results were as expected as they included no drug. However, 
all formulations containing the drug were expected to show zones of inhibition but 
the results showed no zones of inhibition (Table 3.3). This was probably due to the 
contaminents within the formulations which may be acting as a source of nutrient 
for bacterial growth. 
 It was expected to get a zone of inhibition upon using ethosomal formulations as 
ethosomes contain 40% ethanol even though ethanol is used as antiseptic. 
Throughout this series of experiment, it has been proved that ethanol has less 
antibacterial activity as stated by Macdonnell and Rusell (1999) in which they 
have clearly mentioned that ethanol is effective against viruses. A reason behind 
the unexpected finding for ethosomes is possibly due to the added phospholipid 
and cholesterol that may act as bacterial growth promoter. 
Similarly, Table 3.3 showed propanosomes based on the concentration of propanol 
within the formulation which caused no zone of inhibition, indicating they have no 
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killing effect of bacteria. This was also the case when CHX was included within 
propanosome formulations. In these experiments, propanosomes were supposed to 
show a zone of inhibition as propanol is considered slightly more effective against 
bacteria compared to ethanol (Coulthard & Skyes, 1936). The possible reason 
could be the added phospholipids and surfactants that were utilised by the bacteria 
as a source of nutrition for bacterial growth. 
 
Table 3.1 (sr. no 1-13) showed a selection of formulations chosen for investigation 
as to check whether  they cause zone of inhibition as in previous experiment the 
formulations were not showing any zone of inhibition. Table 3.1 (sr. no. 14 and 
15) further demonstrated an investigation aiming to determine the specific 
concentration of ethanol (i.e. whether 20 and 40%) that would be effective against 
bacterial growth. The results showed no zone of inhibition, which indicates that 
even 20 or 40% of ethanol was not effective against bacteria. The possible reason 
could be the low amount of solution used for analysis. 
 Similarly, Table 3.1 (sr no. 16-18) was presented to investigate the concentration 
of propanol required to inhibit the bacterial growth. The concentrations 
investigated were 20, 40 and 70% propanol in 0.9 % NaCl solution. As for 
ethanol, none of these solutions showed a zone of inhibition, possibly also because 
of the low amount used. Perhaps the clinical studies have been demonstrated that 
70 % (p/v) propan-2-ol have been demonstrated as significantly a better skin 
disinfectant in patients receiving pre-operative skin antisepsis on abdominal sites 
(shown n = 106) (Hibbard et al., 2000). 
4.4 TEM results 
Transmission electron microscopy indicates the general images of propanosomal 
vesicular formation. At 100 nm magnification, the particles seemed to be 
unilamellar vesicles. The image indicated that the propanosomal formulation was 
composed of small unilamellar vesicles (Figure 3.27).  
When drug loaded propanosomes were observed at 500 nm magnifications under 
TEM, the image shown that the lipid bilayers were disrupted which might be due 
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to addition of the drug. However, no drug particles were observed, as the 
concentration of added drug was too low; also it seems that no clear propanosomes 
were formed (Figure 3.28). The Figure also showed the disrupted structure of the 
vesicles probably due to higher concentration (40% propanol) included in the 
formulation. The image has clearly indicated membrane disruption and open 
structures (Figure 3.29). 
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5 Conclusion and Scope of 
Future studies 
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5.1 Conclusion 
Novel lipidic formulations of propanosomes were successfully prepared using the 
thin-film hydration technique. They were ultra-deformable and reduced in size 80-
100 nm upon passing through PMFP via lipid extrusion. The propanosomes also 
acted as carriers for CHX base for potential skin treatment application.  
The reported results showed that the mean size of propansomes was inherited from 
transferosomes and the deformability and charge characteristics of ethosomes. The 
plan of combining the preparatory method for trasnsfersomes and ethosomes were 
successfully achieved in the form of propanosomes. However, the agar disk 
diffusion antimicrobial testing showed no antimicrobial property of propanosomes 
with or without the drug, CHX. However, it was acknowledged that the drug 
content may have been too low for any significant antimicrobial effect to be 
observed. The use of surfactant Span 80 as the edge activator for the preparations 
of propanosomes provided better results so it can be optimised for further testing. 
TEM images have indicated SUVs of propanosomes, but the particle sizes were all 
disrupted. The reason is unknown, but this probably may have been due to the 
preparatory ingredients such as the inclusion of propanol, an alcohol similar to 
ethanol that is known to induce structural differences in lipidic membranes. The 
results also show the interesting property of the propanosomes such as smaller 
size, positive surface charge, ultradeformability which can be investigated further 
for skin treatment.  
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5.2 Scope for future studies 
 
1) The concentration of added drug should be increased followed by 
investigating the antimicrobial efficiency. 
 
2) Different forms of CHX such as base and salts should be tested 
individually by incorporating them in the formulation with the aim of 
enhancing the antimicrobial effects. 
 
3) DSC studies can be performed to intensify and expand the knowledge of 
drug interaction with the bilayers of lipid-based vesicles.  DSC could also 
provide information on the role of excipients used in bilayer fluidity and 
permeability.  
 
4) Stability testing can be performed for the formulations by keeping them for 
six months and checking their size and zeta potential and their 
ultradeformability. 
 
5) Propanosomes with 20% propanol added showed no anti-microbial effect 
so intermediate conentrations (25, 30, 20% (v/v) should be tested for 
further investigastion. 
 
6) Propanosomes and other formulations deformability studies can be 
performed on a skin model. 
 
7) Transfersomes made from combinations of Span 80 and Tween 80 may 
produce better MLVs which are more stable compared to Tween 80. 
Further studies can be performed based on their combitional preparation 
(Muthprasanna, 2012). 
 
8) The concentration of Span 80 in the formulation should be optimized 
further for testing the entrapment efficiency of the drug. 
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9)  The agar disk diffusion test may not be the best test to check the 
susceptibility of the bacteria. Hence using an alternative bacterial 
sensitivity test is required.  
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